



Europäisches Patentamt
European Patent Office
Office européen des brevets

Publication number:

0 153 152
A2

12

EUROPEAN PATENT APPLICATION

21 Application number: **85300877.7**

51 Int. Cl.⁴: **C 07 D 487/04, A 61 K 31/505**
// (C07D487/04, 239:00, 235:00)

22 Date of filing: **14.02.85**

31 Priority: **15.02.84 US 580409**

71 Applicant: **SYNTEX (U.S.A.) INC., 3401 Hillview Avenue, Palo Alto, California 94304 (US)**

43 Date of publication of application: **28.08.85**
Bulletin 85/35


72 Inventor: **Fried, John H., 1238 Martin Avenue, Palo Alto California 94301 (US)**
Inventor: **Venuti, Michael C., 44321 21st street, San Francisco California 94114 (US)**

84 Designated Contracting States: **AT BE CH DE FR GB IT LI LU NL SE**

74 Representative: **Armitage, Ian Michael et al, MEWBURN ELLIS & CO. 2/3 Cursitor Street, London EC4A 1BQ (GB)**

64 (2-Oxo-1,2,3,5-tetrahydroimidazo-/2,1-b/quinazoliny)-oxyalkylamides, their preparation, compositions containing them and their use in making medicaments.

67 Compounds according to the formula



and their pharmaceutically acceptable salts.

These compounds are 3',5'-cyclic AMP phosphodiesterase inhibitors useful as antithrombotic agents and the like in mammals.

EP 0 153 152 A2

5

-1-

10

(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolinyl)oxyalkylamides
their preparation, compositions containing
them and their use in making medicaments

15 This invention relates to novel substituted
1,2,3,5-tetrahydroimidazo[2,1-b]quinazolines which
possess phosphodiesterase inhibiting properties.

20


Publication of possible interest herein are: F.
Kienzle, et al, Eur. J. Med., 1982-17, N°6d, pp 547-556
disclosing 1,5-dihydroimidazoquinazolinones as blood
25 platelet aggregation inhibitors; Japanese patent
54-163825; and U.S. Patent 3,932,407. These references
are relevant primarily for their disclosure of similiarly
acting compounds, not because the compounds therein are
structural analogues to the compounds herein.
30

35

7490K

24250-FF

In a first aspect this invention relates to compounds of the formula



10

and the pharmaceutically acceptable salts thereof wherein:

m and n are integers of 1 to 6;

R₁ is hydrogen or alkyl of 1 to 4 carbon;

15 R₂ is hydrogen or R₁ and R₂ are combined to form a carbonyl group;

R₃ is hydrogen, alkyl of 1 to 6 carbons, phenyl, benzyl, hydroxy lower alkyl and its acylates, carbamoyl alkyl, carboxyalkyl, alkoxycarbonylalkyl or amino acid side chains;

20 R₄ is hydrogen, alkyl of 1 to 6 carbons, benzyl, or hydroxy lower alkyl;

R₅ is hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms or cycloalkyl lower alkyl of 4 to 12 carbon atoms wherein the cycloalkyl ring
 25 is unsubstituted or substituted with a lower alkyl, lower alkoxy, -OH, -OCOR₆, halo, -NH₂, -N(R₆)₂, -NHCOR₆, -COOH, or -COO(R₆) group wherein R₆ is lower alkyl; phenyl or phenyl lower alkyl wherein phenyl is unsubstituted or substituted with 1 or more lower
 30 alkyl, halo or lower alkoxy groups or an -NH₂, -N(R₆)₂, -NHCOR₆, -COOH, or -COOR₆ group wherein R₆ is lower alkyl;

Y is hydrogen, alkyl of 1 to 4 carbon atoms, halo or lower alkoxy; and

Z is $-OR_7$ or $-NR_7R_8$ wherein R_7 and R_8 are independently hydrogen or lower alkyl.

In a second aspect this invention relates to
 5 pharmaceutically acceptable compositions of one or more compounds according to Formula I wherein said compounds are combined with at least one pharmaceutically acceptable excipient.

In yet another aspect this invention relates to
 10 such compounds for pharmaceutical use, e.g. in inhibiting 3',5'-cyclic AMP phosphodiesterase activity in a mammal, particularly, a human, or in treating heart failure by stimulating suppressed heart activity which occurs during heart failure, or in inhibiting tumor growth.


15

20

In yet another aspect this invention relates to a process for making a compound of Formula I which method comprises treating a compound of Formula II

25

30



(II)


wherein

35

7490K


24250-FF

m, n, R₁, R₂, R₃, R₅, Y and Z are as defined above but wherein R₅, R₇ and R₈ are not hydrogen, with an N-alkylating agent, or treating a compound of Formula III with base



and wherein

m, n, R₁, R₂, R₃, R₄ and Y are as defined above and Z is -OR₇ wherein R₇ is lower alkyl with base; or treating a compound of Formula IV




25

serially with a halocyanogen and base and wherein m, n, R₁, R₂, R₃, R₅, and Y are defined above, Z is -OR₇ wherein R₇ is lower alkyl or -NR₇R₈ wherein R₇ and R₈ are hydrogen or lower alkyl and R₆ is alkyl of 1 to 6 carbon atoms; or

30

treating a compound of the Formula V



- 5 with 2-methylthiohydantoin and wherein m, n and Y are defined above and Z is -OR₇ wherein R₇ is lower alkyl or -NR₇R₈ wherein R₇ and R₈ are defined above to yield a compound of Formula (I) wherein R₁ and R₂ are
- 10 a carbonyl group and R₃ and R₄ are both hydrogen; or
 converting the free acid of a compound of Formula I to a pharmaceutically acceptable salt; or
 converting a salt to the compound of Formula I to the corresponding free acid; or
- 15 converting the free base of a compound of Formula I to a pharmaceutically acceptable acid addition salt; or
 converting a salt to the compound of Formula I to the corresponding free base; or
 converting a salt of the compound of Formula I to a
- 20 corresponding pharmaceutically acceptable acid addition salt.

These compounds are potent inhibitors of human

25 platelet 3',5'-cyclic AMP phosphodiesterase activity. As a consequence, these compounds inhibit the ADP-induced aggregation of human platelets. Thus, these compounds are useful in the prevention or treatment of a variety of conditions related to platelet aggregation and

30 thrombosis, for example, intravascular thrombosis, prevention of coronary thrombosis, prevention of transient ischemic episodes and prevention of platelet thrombosis and the prevention of thrombosis, thrombocytopenia or platelet activation associated with

35


the use of prosthetic devices (artificial heart valves, etc.).

3',5'-Cyclic AMP is known to regulate the activity of numerous enzymes and mediates the action of several hormones. Studies have demonstrated a deficiency in this cyclic AMP or an increase in the activity of a high affinity 3',5'-cyclic AMP phosphodiesterase is associated with a variety of disease states. As inhibitors of 3',5'-cyclic AMP phosphodiesterase, compounds of this type are useful in the treatment or prevention of hypertension, asthma, diabetes, obesity, immune disfunctions, psoriasis, inflammation, cardiovascular disease, tumor metastasis, cancer and hyperthyroidism. A full and more complete description of the various prophylactic and therapeutic activities of cyclic AMP phosphodiesterase inhibiting compounds can be found in the following several references: Amer, S. M., "Cyclic Nucleotides As Targets For Drug Design," Advances in Drug Research, Vol. 12, 1977, Acedamic Press, London, pp 1-38; Weinryh, I. et al, J. Pharm. Sci., pp 1556-1567, (1972); Amer, S. M. & W. E. Kreighbaum, J. Pharm. Sci., V 64, pp 1-37, (1975); and Harris, D. N., et al, Enzyme Inhibitors As Drugs, McMillan & Co., Ed - M. Sandler, pp 127-146, (1980).


The compounds of the present invention also have inotropic activity. They can strengthen myocardial contraction force by which the heart ventricles can pump the blood into the periphery. Consequently, these compounds also are useful in treating myocardial failure.

Furthermore, the compounds of the present invention also have anti-metastatic activity.

The compounds of the present invention are numbered as follows:



For the purpose of this disclosure, the compounds of the present invention are represented as having the single structural formulation represented by Formula I. However, when R_4 is hydrogen, compounds of Formula I can exist in several possible tautomeric forms established by the following core structures:



All tautomers are part of the present invention.

25 The compounds of this invention may be prepared as structural isomers wherein the oxyalkylamide side chain is substituted on the benzene ring at any of the four different available positions. This fact is graphically represented in the generic formula by the drawing of the

30 line into the benzene ring without it being directed to a particular carbon. In addition, the Y substituent or substituents may be present at any of one or more of the remaining ring positions as indicated by Formula I.

Also within the scope of this invention are the

35 optical isomers of those compounds having an asymmetric

center, such as when positions 3 and/or 4 of the 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one structure are substituted with a substituent other than hydrogen. In addition R₅ may have an asymmetric center.

5 Accordingly, the compounds of the present invention may be prepared either in optically active form or as racemic mixtures. Unless otherwise specified, where appropriate, products of the various synthetic steps described herein will be a racemic mixture. However, the
10 scope of the subject invention herein is not limited to the racemic mixture, but is to encompass the separated individual optical isomers of the disclosed compounds.

If desired, the compounds herein may be resolved into their optical antipodes by conventional resolution means, for example, by separation (e.g. fractional
15 crystallization) of the diastereomeric salts formed by the reaction of these compounds with optically active acids. Exemplary of such optically active acids are the optically active forms of camphor-10-sulfonic acid,
20 2-bromo-camphor- α -sulfonic acid, camphoric acid, menthoxyacetic acid, tartaric acid, malic acid, diacetyltartaric acid, pyrrolidine-5-carboxylic acid and the like. The separated pure diastereomeric salts may then be cleaved by standard means to afford the
25 respective optical isomers.

For the purpose of this invention, the following phrases should be understood to have the recited meaning.

When reference is made to "alkyl of 1 to 6 carbon atoms" it is meant that there is a branched or unbranched
30 saturated hydrocarbon chain containing, in total, that number of carbon atoms. The phrase refers specifically to such substituents as, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, tert-butyl, n-pentyl, n-hexyl and the like. The terms "alkyl of 1 to 4 carbon
35 atoms" and "lower alkyl" are used interchangeably and

mean methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl and the like.

"Lower alkoxy" means the group -OR wherein R is lower alkyl as defined in the foregoing paragraph.

5 In the instance where the nitrogen is substituted with an hydroxyalkyl substituent, that hydroxy function can be converted to an ester by reaction with a carboxylic acid. Such an acid may be any unbranched or branched aliphatic acid having 1 to 6 carbon atoms such
10 as, for example, formic acid, acetic acid, propionic acid, butyric acid, pentanoic acid, hexanoic acid or an isomer of these acids which has up to 6 carbon atoms and is fully saturated. These are referred to herein as "aliphatic acylates of 1 to 6 carbon atoms." In
15 addition, the carboxylic acid may be an aryl acid, exemplified by benzoic acid and having up to 7 to 12 carbon atoms. Representative radicals are, in addition to benzoic acid, phenylacetic acid, 3-phenylpropionic acid, 4-phenylbutyric acid, 6-phenylhexanoic acid and the
20 like. Such acids serve to define and exemplify the term "aryl acylates of 7 to 12 carbon atoms."

The phrase "unsubstituted or substituted" is used herein in conjunction with cycloalkyl and aryl
25 substituents to indicate the ring may have on it only hydrogen or, alternatively, may be substituted one or more of the enumerated radicals as specifically indicated.

"Cycloalkyl of 3 to 8 carbon atoms" refers to a saturated aliphatic ring which contains 3 to 8 carbon atoms and which is substituted directly onto the nitrogen
30 without any intervening methylene groups. Such radicals are, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

When reference is made to "cycloalkyl lower alkyl of 4 to 12 carbon atoms" it is meant thereby that the
35 substituents denoted as cycloalkyl of 3 to 8 carbon atoms

in the preceding paragraph are attached to the nitrogen by means of a saturated branched or unbranched carbon chain which may have 1 to 4 carbon atoms. Such substituents are, for example, cyclobutylmethyl, 5 4-cyclobutylbutyl, cyclopentylmethyl, 4-cyclopentylbutyl, cyclohexylmethyl, 4-cyclohexylbutyl, cycloheptylmethyl and 4-cycloheptylbutyl, to name a few examples.

In addition, the cycloalkyl or cycloalkyl lower alkyl radicals recited in the two foregoing paragraphs 10 may be substituted with a radical chosen from the group consisting of lower alkyl, lower alkoxy, -OH, -OCOR₆, halo, -NH₂, -N(R₅)₂, -NHCOR₅, -COOH, and -COO(R₅) group wherein R₅ is lower alkyl.

"Phenyl lower alkyl" means a group having at least 15 one and up to four methylene groups with an ω-phenyl group. In this instance the carbon chain is linear, not branched. The phenyl group may be unsubstituted, i.e. contain only hydrogen, or it may be substituted with up to 5 substituents of a single functionality or a 20 combination of the several recited substituents. Examples of unsubstituted phenyl lower alkyl are benzyl, phenethyl, phenylpropyl and phenylbutyl. Examples of substituted phenyl lower alkyl are 4-halophenylalkyl, 2,4-dihalophenylalkyl, 2,4,6-trihalophenylalkyl or 25 2,3,4,5,6-pentahalo-phenylalkyl wherein halo is as defined below.

In addition the phenyl group may be substituted with one or more lower alkyl groups such as methyl, ethyl, 30 propyl or the like. One or more lower alkoxy groups may also be substituted on the phenyl ring. Also, phenyl may be substituted with a radical chosen from the group comprised of -NH₂, -N(R₅)₂, -NHCOR₅, -COOH, and -COOR₅ group wherein R₅ is lower alkyl.

The term "halo" refers to fluoro, chloro and bromo 35 and iodo.

The prefix D- and L- are used to describe the individual optical isomers having an asymmetric center at the 3 or 4 position in the 1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-2-one structure.

5 Perhexylenyl refers to the substituent dicyclohexyl-2-(2-piperidyl)ethane which is disclosed in British Patent 1,025,578.

 "Pharmaceutically acceptable salt" refers to those salts which retain the biological properties and efficacy
10 of the free acid or base and which are not biologically or otherwise undesirable, formed with inorganic or organic acids or bases. Inorganic acids which may be used are, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the
15 like. Exemplary organic acids are acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic
20 acid, p-toluenesulfonic acid, salicylic acid and the like.

 The compounds of Formula I in free base form may be converted to the acid addition salts by treating the base with a stoichiometric excess of the appropriate organic or inorganic acid. Typically, the free base is dissolved
25 in a polar organic solvent such as ethanol or methanol, and the acid added thereto. The temperature is maintained between about 0°C and 100°C. The resulting acid addition salt precipitates spontaneously or may be brought out of solution with a less polar solvent.

30 Administration of the active compounds and salts thereof described herein can be via any of the accepted modes of administration for agents which are cyclic AMP phosphodiesterase inhibitors. These methods include oral, parenteral and otherwise systemic or aerosol forms.

35

Depending on the intended mode of administration, the compositions used may be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, or the like, preferably in unit dosage forms suitable for single administration of precise dosages. The compositions will include a conventional pharmaceutical carrier or excipient and an active compound of Formula I or the pharmaceutically acceptable salts thereof and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc.

For oral administration, a pharmaceutically acceptable non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium, carbonate, and the like. Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like. Such compositions may contain 10%-95% active ingredient, preferably 25-70%.

Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or intravenously. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like. In addition, if desired, the pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like,

such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.

5 A more recently devised approach for parenteral administration employs the implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained. See, e.g., U.S. Patent No. 3,710,795 and 3,773,919.

10 For systemic administration via suppository, traditional binders and carriers include, e.g. polyalkylene glycols or triglycerides. Such suppositories may be formed from mixtures containing active ingredient in the range of 0.5%-10%; preferably 1-2%.

15 The amount of active compound administered will of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, and if the intended treatment is to inhibit platelet aggregation, for heart failure or to inhibit tumor growth. In any
20 case, a therapeutically effective amount of the drug either alone or in combination with the various excipients listed above or otherwise known will be administered.

25 Preferred embodiments of the present invention are those compounds wherein m is 1 or 2, n is 3 or 4; R_1 , R_2 and R_3 are hydrogen and R_4 is hydrogen or methyl, or compounds wherein n is 3 or 4, R_1 , R_2 and R_4 are hydrogen, R_3 is alkyl of 1 to 6 carbon atoms, phenyl, benzyl, hydroxy lower alkyl and its acylates or
30 carbamoyl alkyl and their optical isomers.

More preferred embodiments are those compounds wherein m is 1; n is 3 or 4; R_1 , R_2 and R_3 are hydrogen; R_4 is hydrogen or methyl, and R_5 is alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon
35 atoms, cycloalkyl lower alkyl of 4 to 12 carbon atoms,


phenyl or phenyl lower alkyl unsubstituted or substituted with 1 or more lower alkyl, halo or lower alkoxy groups; perhexylenyl; Y is hydrogen and Z is -OH or -NH₂.


Most preferred are those compounds wherein m is 1 or 2, n is 3 or 4, R₁, R₂ and R₄ are hydrogen, R₃ is alkyl of 1 to 6 carbon atoms, phenyl, benzyl, hydroxy lower alkyl and its acylates or carbamoyl alkyl and R₅ is alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 8 carbon atoms; Y is hydrogen and Z is -OR wherein R is hydrogen or lower alkyl or -NH₂ and their optical isomers.

PREPARATION AND EXAMPLES

Compounds of the present invention can be made by several methods. In this disclosure, the process for preparing the claimed compounds begins with a hydroxy-2-nitrobenzaldehyde which is reacted with an ω-haloalkylester which serves to introduce the alkyl side chain onto the benzene ring. The ester is then hydrolyzed, converted to the acid chloride and treated with the appropriate secondary ω-amino acid ester or amide. If R₁ is to be a group other than hydrogen, that group is introduced into the compound at this point by treating the amide with an appropriate Grignard reagent, which reacts with the aldehyde function, and then oxidizing the resulting alcohol to the ketone. The aldehyde or ketone-containing amide is then treated with an α-amino acid or a salt thereof followed by a cyclization step employing a halo cyanogen and base. Acid addition salts, etc are prepared from this base as needed or desired.

Compounds of the present invention are prepared by the reaction sequence outlined in the following Reaction Schemes. Z is -OR₇ wherein lower alkyl or -NR₇R₈ as defined above.

REACTION SCHEME A



In Reaction Scheme A, the phenols of Formula (1) are known in the art and a number of them are readily available from commercial sources such as Aldrich Chemical Co., Milwaukee, Wisconsin. They are converted
5 to the ω -(formylnitrophenyl)oxyalkyl esters by treating the phenol with an ω -halo substituted alkyl ester of Formula (2). Generally, the reaction is carried out by mixing a mole equivalent of ω -haloalkylester, or up to
10 a 20% excess thereof, with the parent phenol compound in a dry, dipolar aprotic solvent under an inert atmosphere. Solvents which may be used in this reaction are, for example dimethylformamide, propylene carbonate, ethylene carbonate, diethylcarbonate, dimethylcarbonate,
15 tetrahydrofuran and the like. Dimethylformamide is preferred. Preferably the reaction will be carried out in a predried solvent and will be blanketed under a dry inert atmosphere such as nitrogen.

A molar amount, but up to a 30% excess, of weak base
20 is added to the solution to effect the reaction. This weak base may be, for example, an alkali metal carbonate or the like, preferably potassium carbonate. The reaction requires between about 0.25 and 2 hours at between room temperature and 200°C. Preferably the
25 reaction will be carried out for about 1 hour at about 100°C.

Reaction products are isolated by conventionally known methodologies, preferably by solvent extraction into a compatible organic solvent. The Formula (3)
30 product may be further purified by distillation or other appropriate means.

35

Conversion of the ester to its corresponding acid involves saponification using well-known conditions and reagents. For example a dilute solution of a strong base such as an alkali metal base is added to an alcoholic solution of the ester in small portions and the reaction is allowed to run for about 10 to 60 minutes at a temperature between 0-50°C. Alcohols which may be used as the solvent for this reaction are, for example, methanol, ethanol, propanol and isopropanol or the like, though it is preferable to use ethanol. The base may be, for example, sodium hydroxide, potassium hydroxide, or lithium hydroxide and the like, but it is preferable and most convenient to use sodium hydroxide. While the concentration of the added base may range between 1 and 6N it is preferable to begin with a 3N solution and add it to the reaction mixture in a ratio of 1 part base for every 4 parts of alcohol solution. Preferably the reaction is allowed to run for about 30 minutes at room temperature after which the solution is neutralized with a concentrated solution of a strong acid such as hydrochloric acid or the like and the solvent evaporated. The product is then further isolated by organic solvent extraction. Crystallization from an appropriate organic solvent gives Formula (4) type compounds.

The conversion of Formula (4) acids to the acid chloride of Formula (5) is a known reaction. The reaction is carried out in a stirred solution of acid in a non-polar, non-reactive solvent such as benzene or toluene or the like to which has been added a small amount of a dipolar aprotic solvent such as dimethylformamide or the like by the addition of an acid

35

halide forming agent, preferably an acid chloride forming agent such as oxalyl chloride. The acid chloride forming reagent should be present in about a 25 to 75% molar excess, preferably a 50% excess, in order to effect a stoichiometric conversion of the acid to the acid halide.

The reaction is allowed to proceed at a temperature between about 0-45°C for a time between about 15 minutes and 2 hours. Preferable reaction conditions are about 20°C for about 1 hour by which time the suspended acid should be completely dissolved.

Without further isolation, the solvent in which the acid chloride is dissolved is converted to a polar solvent by repetitive evaporation and dissolution of the acid chloride in the new polar solvent. This polar solvent may be, for example, an ether such as tetrahydrofuran or diethylether, preferably tetrahydrofuran and preferably dry.

Preparation of the amide from the acid chloride is effected by means of the catalyst 4-dimethylaminopyridine (DMAP) under anhydrous conditions and an inert atmosphere. The acid chloride is dissolved in a dipolar aprotic solvent, such as tetrahydrofuran, and added to a solution of the secondary ω -amino acid ester or amide which has been dissolved in a dipolar aprotic solvent containing an organic base, for example a trialkylamine, or the like but preferably triethylamine. The ester or amide will be present in a slight molar excess relative to the acid chloride. The DMAP catalyst is present in the mixture in an amount up to a 10% molar amount relative to the acid chloride. During addition of the acid chloride, the reaction mixture is maintained at a temperature of between -10 to +10°C. The inert atmosphere is preferably provided by the use of dry nitrogen.

The secondary ω -amino acid esters or amides are prepared by the general procedure of Speziale, A. J., E. G. Jaworski, J. Org. Chem., 25, 728 (1960).

When addition of the acid chloride is complete the
5 solution is warmed to between about 15 - 35°C, preferably room temperature, and the reaction is allowed to proceed at that temperature for between about 30 minutes and 4 hours, preferably 2 hours.

When R₁ is alkyl or phenyl, that moiety may be
10 introduced into the compound by reacting the Formula (6) aldehyde with a Grignard reagent or an alkyl lithium compound and then oxidizing the resulting secondary alcohol to the ketone represented by Formula (8).

Alkyl magnesium halide reagents are readily
15 available or may be easily prepared from the alkyl halide and magnesium, a process well-known in the synthetic arts. Formation of the alcohol is effected by adding the aldehyde to a cooled ethereal solution of Grignard reagent wherein the Grignard reagent is present in a 10%
20 molar excess relative to the aldehyde. After addition of the aldehyde is complete, the reaction is refluxed for about 1 to 4 hours, preferably 2 hours. Degradation of the magnesium halide derivative to obtain the alcohol is carried out by dropwise addition of a mineral acid, for
25 example a 25% sulfuric acid solution. This solution is neutralized with a weak base and the alcohol isolated in preparation for treatment with an oxidizing agent to regenerate the carbonyl group.

The oxidation of Formula (7) type compounds is
30 carried out via some strong oxidizing agent under selected conditions which minimize amide oxidation. There may be used, for example, a chromium trioxide-pyridine complex or the like. Preferably the reaction will be carried out under anhydrous conditions
35 under an inert atmosphere and in a polar organic solvent

which is inert to the oxidizing reagent, such as a halogenated hydrocarbon. Reaction temperatures will be between about 0 to 100°C for a period of about 1 to 8 hours. A 10% molar excess of oxidizing agent relative to
5 the alcohol is sufficient to effect the desired oxidation.

Herein a preferred oxidizing reagent is the Collins reagent [J. C. Collins, et al., Tetrahedron Letters, p 3363 (1968)] which employs a chromium trioxide-pyridine complex in a halogenated hydrocarbon solvent system. The
10 reaction is carried out under anhydrous conditions in an inert atmosphere. The preferred organic solvents are for example, methylene chloride, carbon tetrachloride, ethylene chloride, or the like. The inert atmosphere is maintained by the use of a dry inert gas, preferably dry
15 nitrogen. Usually a temperature between about 0 to 50°C for a period of about 0.5 to 5 hours is generally sufficient to effect the reaction. Most preferably the reaction will be carried out in dry methylene chloride under a dry nitrogen atmosphere for about 1 hour at room
20 temperature.

Formula (6) and Formula (8) compounds may then be converted to compounds of Formula (9) by reacting the aldehyde or ketone with an α -amino acid ester. For the purposes of this invention any lower alkyl ester of a
25 naturally occurring α -amino acids or any synthetic α -amino acid ester may be used in the practice of this invention. Generally, the reaction is carried out at a temperature between about 0-50°C, preferably ambient temperature. A time of between 1 to 8 hours is
30 sufficient to effect the reaction though 3-4 hours is preferable. The reaction is generally carried out in a polar solvent such as an alcohol, for example, methanol, ethanol, propanol, or the like in which the aldehyde/ketone and the ester are soluble. It is
35 preferable to add a water-scavenging agent such as

molecular sieves in order to remove water generated during the reaction process.

Initially, a reaction mixture is prepared which contains the carbonyl compound, about a two-fold molar
5 amount of the α -amino acid ester as an acid addition salt, and the water scavenging agent. To this mixture is added a large molar excess of the α -aminocarboxylic acid ester, about 6-10 fold excess. The solution is
10 generally maintained between about 10 to 30°C during this addition process. After addition of the ester is complete, there is added a cyanoborohydride reducing agent in a molar amount of about one-half that of the carbonyl compound. The reaction is allowed to proceed at
15 a temperature between about 10 to 30°C, preferably at room temperature for a period of between about 1 to 6 hours, preferably 3 to 4 hours.

While the reaction product may be isolated for characterization, etc., that is not necessary and it is most convenient to simply remove precipitated solids,
20 i.e., the molecular sieves and borate salts, by filtration, evaporate the solvent and to take up the residue in an organic solvent. This solution may then be washed with a base and brine to remove impurities after which the solvent is removed and the resulting residue
25 used directly in the next reaction step.

Reduction of the nitro group is most conveniently carried out by catalytic hydrogenation. This reaction may be accomplished by conventionally known means. As
30 practiced herein, the residue from the previous reaction step is dissolved in an appropriate solvent such as, for example, a simple alcohol such as methanol or ethanol. A transition metal catalyst which will selectively reduce the nitro group to the amine without affecting the amide or the phenyl ring is preferred. A preferred catalyst is
35 a palladium catalyst and most preferably it will be

palladium on carbon such as the readily available 10% palladium/carbon catalyst.

A small amount of the palladium/carbon catalyst, i.e., between 0.5 and 1.5 grams, will generally be
5 sufficient to effect the reduction. The alcoholic reaction mixture is placed under hydrogen at room temperature and allowed to proceed till an equivalent of hydrogen has been taken up. Isolation of the hydrogenation product is readily accomplished by
10 filtration to remove the catalyst after which the reaction product may be used directly in the following step.

Cyclization of the amine (10) to give (I), wherein R_4 is hydrogen, is achieved by means of a cyanogen
15 halide, preferably the bromide. A 5 to 10% molar excess of cyanogen halide is added to the solution from the previous reaction. The resulting solution is refluxed overnight, preferably about 16 hours.

The resulting reaction mixture is then treated with
20 a solution of a strong base for about 0.5 to 4 hours at a temperature between 0 and 50°C. Bases which may be used to effect this reaction are alkali metal bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide and the like. They are used at a concentration
25 of between about 1 to 6N, preferably 2N. A molar amount of base equivalent to that of the cyanogen halide employed in the previous step is employed in this final reaction step. Preferably the reaction will be allowed to proceed for about 2 hours at room temperature during
30 which time the product generally will precipitate as a powder. The product, Formula I wherein R_4 is hydrogen, can be further isolated and characterized by filtration or centrifugation, followed by drying or by recrystallization from an appropriate organic solvent.
35

Further transformation of compounds where $R_4 = H$ to those where R_4 is alkyl, benzyl, etc is accomplished by treating the former with alkylating agents and a strong base, such as potassium tert-butoxide or sodium
5 hydride in a dipolar aprotic solvent such as dimethyl formamide.

The optical isomers of Formula (I) wherein R_3 is a substituent other than hydrogen can be prepared following the same procedures as described above except while
10 reacting with the carbonyl compound (6) or (8), an optically active α -aminocarboxylic acid ester ($NH_2CHR_3COOR_6$) should be used.

The compounds of Formula I in free base form may be converted to the acid addition salts by treatment with a
15 stoichiometric excess of the appropriate organic or inorganic acid. Typically, the free base is dissolved in a polar organic solvent such as ethanol or methanol, and the acid added thereto. The temperature is maintained between about 0°C and 100°C. The resulting acid addition
20 salt precipitates spontaneously or may be brought out of solution with a less polar solvent.


The acid addition salts of the compounds of Formula I may be decomposed to the corresponding free base by treatment with a stoichiometric excess of a
25 suitable base, such as potassium carbonate or sodium hydroxide, typically in the presence of aqueous solvent, and at a temperature of between about 0°C and 100°C. The free base form is isolated by conventional means, such as extraction with an organic solvent.

30 Salts of the compounds of Formula I may be interchanged by taking advantage of differential solubilities of the salts, volatilities or acidities of the acids, or by treating with the appropriately loaded ion exchange resin. For example, the interchange is
35 effected by the reaction of a salt of the compounds of

Formula I with a slight stoichiometric excess of an acid of a lower pKa than the acid component of the starting salt. This conversion is carried out at a temperature between about 0°C and the boiling point of the solvent.

5 An alternative route for preparing the compounds of Formula (I) wherein $R_2 - R_4$ are hydrogen is exemplified by the following reaction scheme.

REACTION SCHEME B



The compounds of Formula (6) are prepared as described above in Reaction Scheme A.

The compounds of Formula (11) are prepared by oxidizing the corresponding aldehydes with an oxidizing agent such as silver acetate, sodium chlorite-sulfamic acid, chromium trioxide-pyridine complexes or alkylammonium permanganates, for example. Usually the reaction will be carried out under an inert atmosphere in

a dry, nitrogen-containing solvent at a temperature between about 0-50°C for a period of 15 minutes to 3 hours. Preferably the oxidation will be effected by an alkylammonium permanganate such as tetra-butylammonium permanganate in dry pyridine under a dry nitrogen blanket. The reaction is complete in about 1 hour at room temperature.




Reduction of the nitro group to obtain the anthranilic acid compounds of Formula (12) is by catalytic hydrogenation. This reaction employs a heavy metal catalyst dispersed in a simple alcohol containing the nitroacid and put under hydrogen at room temperature until hydrogen uptake is complete. In this instance, it is preferable to add 10% palladium-on-carbon to an ethanolic solution of the nitroacid and place the mixture under about 60 psi hydrogen overnight. Alternatively, the hydrogenation can be carried out with the addition of a mineral acid such as hydrogen chloride, which procedure gives the acid salt directly as a hygroscopic solid.

The amines of Formula (12) are converted directly to Formula I compounds by treating the acids, dissolved in a simple alcohol, with a 2-3 molar excess of 2-methylthiohydantoin. Generally the reaction is carried out under reflux for 1 to 6 hours. Preferably the reaction will be carried out in ethanol under reflux for about 3 hours.

REACTION SCHEME C

Compounds of Formula I may also be prepared from the 7-hydroxy-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one or its 6, 8 or 9-hydroxy analogs by the sequence of steps

set out below.



20

Formula (I)

25

The compounds of Formula 13 are prepared as described in U. S. Patent No. 3,932,407 which is incorporated herein by reference.

30

Alkylation of the hydroxy compounds is achieved by the use of ω -bromoalkanoates (10% molar excess) in a dipolar solvent such dimethylformamide in the same manner described for the preparation of Formula 3 compounds in reaction Scheme A. Ester hydrolysis, to give Formula 14

35

hereinabove for the conversion of Formula 3 compounds to those of Formula 4 in reaction Scheme A.

Amides are prepared directly from the acid by condensation means. The reaction of the acid and an
5 amide-forming agent may be carried out in a dipolar aprotic solvent such as dimethylformamide at a temperature between about 0° - 40°C. For example, first the acid and a 10% molar excess of 1-hydroxybenzotriazole is dissolved in the reaction medium after which a
10 dialkylcarbodiimide, preferable diisopropylcarbodiimide is added. After a period of 0.25 to 2 hours, preferably 1 hour, a solution of methyl N-cyclohexyl glycinate or a like compound (20% molar excess) and N-methyl morpholine (20% molar excess) is added. Overnight stirring at about
15 ambient temperature completes the reaction.

The following Preparations and Examples are set out to illustrate the reaction steps graphically recited above.

20

PREPARATION 1

Methyl N-cyclohexylglycinate

A solution of cyclohexylamine (34.3 ml) and diazobicycloundecene (DBU, 44.8 ml) in dry tetrahydrofuran (500 ml) under a nitrogen atmosphere was
25 cooled to 0°C and was treated dropwise with a solution of methyl bromoacetate (28.4 ml) in tetrahydrofuran (50 ml). After stirring at room temperature overnight, the mixture was filtered to remove precipitated DBU-hydrobromide and the solvent evaporated. The
30 resulting residue was dissolved in ether (200 ml), washed with water (2 x 100 ml), and brine (2 x 100 ml). The organic extract was dried, filtered and evaporated. Fractional distillation provided 21.1 g., b.p. 160-170°C (0.2 mm).

35

PREPARATION 2N-Cyclohexyl Glycinamide

A solution of methyl N-cyclohexyl glycinate (10 g) in methanol (50 ml) was saturated with ammonia and heated
5 overnight at 80°C in a pressure apparatus. The reactor was cooled and the solvent evaporated to give the solid amine, N-cyclohexyl glycinamide, m.p. 112-113°C. Similarly, treatment of methyl N-cyclohexyl glycinate with other amines of the formula R_7R_8NH will give the
10 corresponding cyclohexyl R_7R_8NH N-substituted acetamides (for Example 1).

PREPARATION 3

The preparation of ω -((formyl-nitrophenyl)oxy)-
15 alkyl acid esters, Formula 3, are described herein.

To a solution of 5-hydroxy-2-nitrobenzaldehyde (84.0 g) and ethyl 4-bromobutyrate (86 ml) in dry dimethylformamide (500 ml) blanketed under dry nitrogen was added potassium carbonate (76.0 g). The reaction
20 mixture was heated to 100°C for 1 hour. This mixture was cooled, and the solvent removed by evaporation to give a dark brown syrup. This residue was partitioned between ethyl acetate and saturated sodium carbonate (500 ml each). The organic layer was washed with additional
25 saturated sodium carbonate (3 x 500 ml), and with brine (2 x 500 ml), dried, filtered and evaporated to give a dark brown syrup. Kugelrohr distillation (180°C, 0.2 mm) afforded ethyl 4-((3-formyl-4-nitrophenyl)oxy)butyrate (95 g) as a bright yellow syrup which slowly darkened
30 upon standing.

Using the above procedure, but substituting the appropriate aldehyde for 5-hydroxy-2-nitrobenzaldehyde and alkyl ω -bromoalkanoates for ethyl 4-bromobutyrate there may be prepared, for example, the following
35 compounds:

ethyl 4-(2-chloro-3-formyl-4-nitrophenyl)oxy-
butyrate;
ethyl 4-(3-formyl-4-nitro-5-chlorophenyl)oxy-
butyrate;
5 ethyl 4-(2-chloro-4-nitro-5-formylphenyl)oxy-
butyrate;
ethyl 4-(3-formyl-4-nitro-5-fluorophenyl)oxy-
butyrate;
ethyl 4-(2-fluoro-3-formyl-4-nitrophenyl)oxy-
10 butyrate;
ethyl 4-(2-methyl-3-formyl-4-nitrophenyl)oxy-
butyrate;
ethyl 4-(2-formyl-3-nitro-6-fluorophenyl)oxy-
butyrate;
15 ethyl 4-(2-formyl-3-nitro-4-chlorophenyl)oxy-
butyrate;
ethyl 4-(2-formyl-3-nitro-5-fluorophenyl)oxy-
butyrate;
ethyl 4-(2-formyl-3-nitrophenyl)oxybutyrate;
20 ethyl 4-(2-formyl-3-nitro-5-methylphenyl)oxy-
butyrate;
ethyl 4-(2-formyl-3-nitro-6-fluorophenyl)oxy-
butyrate;
ethyl 4-(2-nitro-3-formylphenyl)oxybutyrate;
25 ethyl 4-(2-nitro-3-formyl-5-methylphenyl)oxy-
butyrate;
ethyl 4-(3-nitro-4-formyl-6-fluorophenyl)oxy-
butyrate;
ethyl 4-(2-chloro-4-formyl-5-nitrophenyl)oxy-
30 butyrate;
ethyl 4-(3-nitro-4-formylphenyl)oxybutyrate;
ethyl 4-(3-nitro-4-formyl-5-methylphenyl)oxy-
butyrate;
ethyl 4-(2-nitro-3-formyl-6-fluorophenyl)oxy-
35 butyrate;

- ethyl 4-(2-nitro-3-formyl-6-chlorophenyl)oxy-
butyrate;
- 5 ethyl 7-(3-formyl-4-nitrophenyl)oxyheptanoate;
ethyl 7-(2-chloro-3-formyl-4-nitrophenyl)heptanoate;
ethyl 7-(2-methyl-3-formyl-4-nitrophenyl)heptanoate;
ethyl 7-(3-formyl-4-nitro-5-chlorophenyl)heptanoate;
ethyl 7-(2-formyl-3-nitrophenyl)heptanoate;
ethyl 7-(2-formyl-3-nitro-4-fluorophenyl)heptanoate;
10 ethyl 7-(2-methyl-3-formyl-4-nitrophenyl)heptanoate;
ethyl 7-(2-formyl-3-nitro-5-chlorophenyl)heptanoate;
ethyl 7-(2-nitro-3-formylphenyl)heptanoate;
ethyl 7-(2-nitro-3-formyl-4-fluorophenyl)heptanoate;
ethyl 7-(2-nitro-3-formyl-6-chlorophenyl)heptanoate;
ethyl 7-(2-nitro-3-formyl-5-methylphenyl)heptanoate;
15 ethyl 7-(3-nitro-4-formylphenyl)heptanoate;
ethyl 7-(3-nitro-4-formyl-5-methylphenyl)heptanoate;
ethyl 5-(2-formyl-3-nitrophenyl)oxypentanoate;
ethyl 5-(2-formyl-3-nitro-4-chlorophenyl)oxy-
pentanoate;
- 20 ethyl 5-(2-formyl-3-nitro-4-methylphenyl)oxy-
pentanoate;
ethyl 5-(2-formyl-3-nitro-6-methylphenyl)oxy-
pentanoate;
- 25 ethyl 5-(3-formyl-4-nitro-5-chlorophenyl)oxy-
pentanoate;
ethyl 5-(2-chloro-3-formyl-4-nitrophenyl)oxy-
pentanoate;
- 30 ethyl 5-(3-formyl-4-nitrophenyl)oxypentanoate;
ethyl 5-(3-nitro-4-formylphenyl)oxypentanoate;
ethyl 5-(3-nitro-4-formyl-5-methylphenyl)oxy-
pentanoate;
- 35 ethyl 5-(3-nitro-4-formyl-6-chlorophenyl)oxy-
pentanoate;
ethyl 5-(3-formyl-4-nitro-6-chlorophenyl)oxy-
pentanoate;

ethyl 5-(2-nitro-3-formylphenyl)oxypentanoate;
ethyl 5-(2-nitro-3-formyl-4-methylphenyl)oxy-
pentanoate;
ethyl 5-(2-nitro-3-formyl-6-chlorophenyl)oxy-
5 pentanoate;
ethyl 6-(2-formyl-3-nitrophenyl)oxyhexanoate;
ethyl 6-(2-formyl-3-nitro-4-chlorophenyl)oxy-
hexanoate;
ethyl 6-(2-formyl-3-nitro-6-chlorophenyl)oxy-
10 hexanoate;
ethyl 6-(3-formyl-4-nitrophenyl)oxyhexanoate;
ethyl 6-(3-formyl-4-nitro-6-chlorophenyl)oxy-
hexanoate;
ethyl 6-(3-formyl-4-nitro-5-methylphenyl)oxy-
15 hexanoate;
ethyl 6-(2-nitro-3-formylphenyl)oxyhexanoate;
ethyl 6-(2-nitro-3-formyl-6-fluorophenyl)oxy-
hexanoate;
ethyl 6-(2-nitro-3-formyl-5-methylphenyl)oxy-
20 hexanoate;
ethyl 6-(3-nitro-4-formylphenyl)oxyhexanoate;
ethyl 6-(3-nitro-4-formyl-6-methylphenyl)oxy-
hexanoate;
ethyl 6-(3-nitro-4-formyl-5-chlorophenyl)oxy-
25 hexanoate;
ethyl 2-(2-chloro-3-formyl-4-nitrophenyl)oxy-
acetate;
ethyl 2-(3-formyl-4-nitrophenyl)oxy-
acetate;
30 ethyl 2-(3-formyl-4-nitro-5-chlorophenyl)oxy-
acetate;
ethyl 2-(2-chloro-4-nitro-5-formylphenyl)oxy-
acetate; and
ethyl 2-(3-formyl-4-nitro-5-fluorophenyl)oxy-
35 acetate.

PREPARATION 4

Ester hydrolysis to give the acids of Formula 4 is described herein.

- To a solution of ethyl 4-(3-formyl-4-nitrophenyl)-oxybutyrate (65 g) in ethanol (400 ml) was added 3N NaOH (100 ml) in small portions. After 30 minutes at room temperature the reaction mixture was acidified with concentrated HCl and the ethanol evaporated. The aqueous residue was extracted with ethyl acetate (4 x 200 ml). The combined organic layers were washed with brine (2 x 200 ml), dried over Na₂SO₄, filtered and evaporated to give a light yellow solid. Trituration with ether afforded 4-(3-formyl-4-nitrophenyl)oxybutyric acid (55 g), m.p. 109-110°C.
- Following the above procedure, the esters prepared as per Preparation 1 are converted to the corresponding acid.

PREPARATION 5

- Conversion of the acids of Formula 4 in Reaction Scheme A to the acid halide, preferably the chloride, preparatory to forming the amide compounds of Formula 6 was carried out as follows:

- To a stirred suspension of 4-(3-formyl-4-nitrophenyl)oxybutyric acid (12.65 g) in benzene (50 ml) and dimethylformamide (0.5 ml) was added oxalyl chloride (4.40 ml) in small portions. When all the acid had been dissolved, the mixture was stirred for an additional 30 minutes. Evaporation of the solvent gave a thick syrup which was redissolved in dry tetrahydrofuran (50 ml) and reevaporated twice. The final residue of crude acid chloride was dissolved in tetrahydrofuran (50 ml) and used without further purification in the next reaction step.

35

Proceeding in a similar manner, the acids prepared as per Preparation 2 are converted to the corresponding acid chloride.

5

PREPARATION 6

Preparation of the acetates represented by Formula 6 is carried out by the following reaction.

A tetrahydrofuran solution of
4-(3-formyl-4-nitrophenyl)oxybutyric acid chloride was
10 added dropwise to a solution of methyl
N-cyclohexylglycinate (12.6 g, 50 mmol), triethylamine
(9.0 ml) and 4-dimethylaminopyridine (0.6 g) in dry
tetrahydrofuran (250 ml). When addition of the acid
chloride was complete the reaction was stirred at room
15 temperature for 1 hour. The mixture was evaporated, the
residue dissolved in ethyl acetate, and the organic layer
washed in 1 M HCl three times, with brine twice and dried
over Na₂SO₄, filtered and evaporated to give methyl
2-(N-cyclohexyl-4-(3-formyl-4-nitrophenyl)-
20 oxybutyramid-1-yl)acetate as a thick syrup.

Using this procedure and substituting the appropriate secondary amine and acid chloride for those described, there may be prepared the following representative compounds:

- 25 methyl 2-(N-cyclohexyl-4-(3-formyl-4-nitro-
phenyl)oxybutyramidyl)acetate;
methyl 2-(N-cyclohexylmethyl-4-(3-formyl-4-nitro-
phenyl)oxybutyramidyl)acetate;
methyl 2-(N-hexyl-4-(3-formyl-4-nitrophenyl)oxy-
30 butyramidyl)acetate;
methyl 2-(N-methyl-4-(3-formyl-4-nitrophenyl)oxy-
butyramidyl)acetate;
methyl 2-(N-ethyl-4-(3-formyl-4-nitrophenyl)oxy-
butyramidyl)acetate;

35

- methyl 2-(N-pentyl-4-(3-formyl-4-nitrophenyl)oxy-
butyramidyl)acetate;
- methyl 2-(N-cyclopentyl-4-(3-formyl-4-nitrophenyl)-
oxybutyramidyl)acetate;
- 5 methyl 2-(N-cyclopropylmethyl-4-(3-formyl-4-nitro-
phenyl)oxybutyramidyl)acetate;
- methyl 2-(N-cycloheptyl-4-(3-formyl-4-nitro-
phenyl)oxybutyramidyl)acetate;
- methyl 2-(N-cyclopentylbutyl-4-(3-formyl-4-nitro-
10 phenyl)oxybutyramidyl)acetate;
- methyl 2-(N-cyclopentylmethyl-4-(3-formyl-4-nitro-
phenyl)oxybutyramidyl)acetate;
- methyl 2-(N-phenyl-4-(3-formyl-4-nitrophenyl)oxy-
butyramidyl)acetate;
- 15 methyl 2-(N-benzyl-4-(3-formyl-4-nitrophenyl)oxy-
butyramidyl)acetate;
- methyl 2-(N-diphenylmethyl-4-(3-formyl-4-nitro-
phenyl)oxybutyramidyl)acetate;
- methyl 2-(N-cyclohexyl-4-(2-formyl-3-nitrophenyl)-
20 oxybutyramidyl)acetate;
- methyl 2-(N-n-hexyl-4-(2-formyl-3-nitro-
phenyl)oxybutyramidyl)acetate;
- methyl 2-(N-methyl-4-(2-formyl-3-nitro-
phenyl)oxybutyramidyl)acetate;
- 25 methyl 2-(N-phenyl-4-(2-formyl-3-nitrophenyl)oxy-
butyramidyl)acetate;
- methyl 2-(N-benzyl-4-(2-formyl-3-nitrophenyl)oxy-
butyramidyl)acetate;
- methyl 2-(N-phenyl-4-(2-nitro-3-formylphenyl)oxy-
30 butyramidyl)acetate;
- methyl 2-(N-cyclohexyl-4-(2-nitro-3-formylphenyl)-
oxybutyramidyl)acetate;
- methyl 2-(N-methyl-4-(2-nitro-3-formylphenyl)-
oxybutyramidyl)acetate;
- 35

- methyl 2-(N-benzyl-4-(2-nitro-3-formylphenyl)-oxybutyramidyl)acetate;
methyl 2-(N-cyclohexyl-4-(3-nitro-4-formylphenyl)oxybutyramidyl)acetate;
5 methyl 2-(N-methyl-4-(3-nitro-4-formylphenyl)oxybutyramidyl)acetate;
methyl 2-(N-n-hexyl-4-(3-nitro-4-formylphenyl)oxybutyramidyl)acetate;
methyl 2-(N-phenyl-4-(3-nitro-4-formylphenyl)oxy-
10 butyramidyl)acetate;
methyl 2-(N-benzyl-4-(3-nitro-4-formylphenyl)oxybutyramidyl)acetate;
methyl 2-(N-diphenylmethyl-4-(3-nitro-4-formylphenyl)oxybutyramidyl)acetate;
15 methyl 2-(N-cyclohexyl-4-(3-formyl-4-nitrophenyl)oxybutyramidyl)hexanate;
methyl 2-(N-cyclohexyl-4-(3-formyl-4-nitrophenyl)oxybutyramidyl)hexanate;
methyl 2-(N-cyclohexylmethyl-4-(3-formyl-4-nitro-
20 phenyl)oxybutyramidyl)hexanate;
methyl 2-(N-hexyl-4-(3-formyl-4-nitrophenyl)oxybutyramidyl)hexanate;
methyl 2-(N-methyl-4-(3-formyl-4-nitrophenyl)oxybutyramidyl)hexanate;
25 methyl 2-(N-ethyl-4-(3-formyl-4-nitrophenyl)oxybutyramidyl)hexanate;
methyl 2-(N-cyclohexyl-7-(3-formyl-4-nitrophenyl)oxyheptanamidyl)acetate;
methyl 2-(N-benzyl-7-(3-formyl-4-nitrophenyl)oxy-
30 heptanamidyl)acetate;
methyl 2-(N-methyl-7-(3-formyl-4-nitrophenyl)oxyheptanamidyl)acetate;
methyl 2-(N-diphenylmethyl-7-(3-formyl-4-nitrophenyl)oxyheptanamidyl)acetate;
35

- methyl 2-(N-cyclohexyl-7-(2-formyl-3-nitro-4-chlorophenyl)oxyheptanamidyl)acetate;
methyl 2-(N-methyl-7-(2-formyl-3-nitrophenyl)-oxyheptanamidyl)acetate;
5 methyl 2-(N-n-butyl-7-(2-formyl-3-nitrophenyl)oxyheptanamidyl)acetate;
methyl 2-(N-phenyl-7-(2-formyl-3-nitrophenyl)oxyheptanamidyl)acetate;
methyl 2-(N-methyl-7-(2-formyl-3-nitrophenyl)oxy-
10 heptanamidyl)acetate;
methyl 2-(N-benzyl-7-(2-formyl-3-nitrophenyl)oxyheptanamidyl)acetate;
methyl 2-(N-phenyl-7-(2-nitro-3-formylphenyl)oxyheptanamidyl)acetate;
15 methyl 2-(N-methyl-7-(2-nitro-3-formylphenyl)oxyheptanamidyl)acetate;
methyl 2-(N-cyclohexyl-7-(2-nitro-3-formylphenyl)oxyheptanamidyl)acetate;
methyl 2-(N-n-butyl-7-(3-nitro-4-formylphenyl)oxy-
20 heptanamidyl)acetate;
methyl 2-(N-benzyl-7-(3-nitro-4-formylphenyl)oxyheptanamidyl)acetate;
methyl 2-(N-cyclohexyl-5-(3-formyl-4-nitrophenyl)oxypentanamidyl)acetate;
25 methyl 2-(N-methyl-5-(3-formyl-4-nitrophenyl)oxypentanamidyl)acetate;
methyl 2-(N-hexyl-5-(3-formyl-4-nitrophenyl)oxypentanamidyl)acetate;
methyl 2-(N-cyclopentyl-5-(3-formyl-4-nitro-
30 phenyl)oxypentanamidyl)acetate;
methyl 2-(N-phenyl-methyl-2-(N-methyl-5-(3-formyl-4-nitrophenyl)oxypentanamidyl)acetate;
methyl 2-(N-benzyl-5-(3-formyl-4-nitrophenyl)oxy-
35 pentanamidyl)acetate;

- methyl 2-(N-cyclohexyl-5-(2-formyl-3-nitro-4-chlorophenyl)oxypentanamidyl)acetate;
methyl 2-(N-methyl-5-(2-formyl-3-nitrophenyl)-oxypentanamidyl)acetate;
5 methyl 2-(N-hexyl-5-(2-nitro-3-formylphenyl)oxypentanamidyl)acetate;
methyl 2-(N-phenyl-5-(2-nitro-3-formylphenyl)oxypentanamidyl)acetate;
methyl 2-(N-diphenylmethyl-5-(2-nitro-3-formyl-10 phenyl)oxypentanamidyl)acetate;
methyl 2-(N-cyclohexyl-5-(3-nitro-4-formylphenyl)oxypentanamidyl)acetate;
methyl 2-(N-methyl-5-(3-nitro-4-formylphenyl)-oxypentanamidyl)acetate;
15 methyl 2-(N-phenyl-5-(3-nitro-4-formylphenyl)oxypentanamidyl)acetate;
methyl 2-(N-hexyl-2-(3-formyl-4-nitrophenyl)oxyacetamidyl)acetate;
methyl 2-(N-phenyl-2-(3-formyl-4-nitrophenyl)-20 oxyacetamidyl)acetate;
methyl 2-(N-cyclohexyl-2-(2-formyl-3-nitro-4-chlorophenyl)oxyacetamidyl)acetate;
methyl 2-(N-methyl-2-(2-formyl-3-nitrophenyl)oxyacetamidyl)acetate;
25 methyl 2-(N-hexyl-2-(2-formyl-3-nitrophenyl)-oxyacetamidyl)acetate;
methyl 2-(N-phenyl-2-(2-formyl-3-nitrophenyl)oxyacetamidyl)acetate;
methyl 2-(N-phenyl-2-(2-nitro-3-formylphenyl)-30 oxyacetamidyl)acetate;
methyl 2-(N-cyclohexyl-2-(2-nitro-3-formylphenyl)-oxyacetamidyl)acetate;
methyl 2-(N-methyl-2-(2-nitro-3-formylphenyl)-oxyacetamidyl)acetate;
35

- methyl 2-(N-benzyl-2-(2-nitro-3-formylphenyl)-oxyacetamidyl)acetate;
- methyl 2-(N-cyclopentyl-2-(3-nitro-4-formylphenyl)oxyacetamidyl)acetate;
- 5 methyl 2-(N-cyclohexyl-2-(3-nitro-4-formylphenyl)oxyacetamidyl)acetate;
- methyl 2-(N-methyl-2-(3-nitro-4-formylphenyl)oxyacetamidyl)acetate;
- methyl 2-(N-cyclohexyl-6-(3-formyl-4-nitrophenyl)oxyhexanamidyl)acetate;
- 10 methyl 2-(N-phenyl-6-(3-formyl-4-nitrophenyl)oxyhexanamidyl)acetate;
- methyl 2-(N-hexyl-6-(3-formyl-4-nitrophenyl)oxyhexanamidyl)acetate;
- 15 methyl 2-(N-cyclohexyl-6-(2-formyl-3-nitro-4-chlorophenyl)oxyhexanamidyl)acetate;
- methyl 2-(N-hexyl-6-(2-formyl-3-nitrophenyl)oxyhexanamidyl)acetate;
- methyl 2-(N-methyl-6-(2-formyl-3-nitrophenyl)oxyhexanamidyl)acetate;
- 20 methyl 2-(N-phenyl-6-(2-formyl-3-nitrophenyl)oxyhexanamidyl)acetate;
- methyl 2-(N-benzyl-6-(2-formyl-3-nitrophenyl)oxyhexanamidyl)acetate;
- 25 methyl 2-(N-cyclohexyl-6-(2-nitro-3-formylphenyl)oxyhexanamidyl)acetate;
- methyl 2-(N-benzyl-6-(2-nitro-3-formylphenyl)oxyhexanamidyl)acetate;
- methyl 2-(N-methyl-6-(2-nitro-3-formylphenyl)oxyhexanamidyl)acetate;
- 30 methyl 2-(N-cyclopentyl-6-(3-nitro-4-formylphenyl)oxyhexanamidyl)acetate;
- methyl 2-(N-methyl-6-(3-nitro-4-formylphenyl)oxyhexanamidyl)acetate; and
- 35

methyl 2-(N-benzyl-6-(3-nitro-4-formylphenyl)oxyhexanamidyl)acetate.

PREPARATION 7

5 A solution of 4-(3-formyl-4-nitrophenyl)oxybutyric acid chloride was added dropwise to a solution of N-cyclohexyl glycinamide (7.8 g) and sodium carbonate (6.90 g) in aqueous tetrahydrofuran cooled to 5°C. The reaction was stirred at room temperature for 1 hour, then
10 extracted with ethyl acetate. The organic extract was washed with saturated sodium bicarbonate three times, 3 x 1 M HCl and 2 x brine, filtered and the solvent evaporated to give 2-(N-cyclohexyl-4-(3-formyl-4-nitrophenyl)oxybutyramidyl)acetamide as a solid, m.p.
15 104-105°C. Similarly, treatment of cyclohexyl R₇R₈-N-substituted acetamides from Preparation 2 gives the corresponding 2-(N-cyclohexyl-4-(3-nitro-4-formylphenyl)-oxybutyramidyl-R₇R₈-N-substituted acetamides.

20

PREPARATION 8

Compounds wherein R₁ is alkyl are prepared by a two step process the first of which is as follows.

Into a tetrahydrofuran solution of methyl Grignard
25 reagent (120 mmol), either purchased from commercial sources or freshly generated from the corresponding halide and elemental magnesium, was added dropwise a solution of methyl 2-(N-cyclohexyl-4-(3-formyl-4-nitrophenyl)oxybutyramid-1-yl)acetate (35 g) in
30 tetrahydrofuran (200 ml). The resulting mixture was warmed to reflux for one hour, then cooled and quenched with saturated aqueous ammonium chloride. Evaporation of the tetrahydrofuran followed by extraction with ethyl

35

acetate provided methyl 2-(N-cyclohexyl-4-(3-(1-hydroxyethyl)-4-nitrophenyl)oxybutyramidyl)acetate (30 g).

Proceeding in a similar manner, but substituting the
5 the appropriate reagents and a compound whose preparation is described in Preparation 6, all the compounds of Preparation 6 are converted to their corresponding 1-hydroxyethyl analog.

10

PREPARATION 9

Oxidation of the secondary alcohols from Preparation 8 is carried out by the following method.

Anhydrous chromium trioxide, 8 g, was added to a stirred solution of 60 ml of dry pyridine in 200 ml of
15 dry dichloromethane and stirred under a dry nitrogen atmosphere at about 20°C for 15 minutes. A solution of 27 g of methyl 2-(N-cyclohexyl-4-(3-(1-hydroxyethyl)-4-nitrophenyl)oxybutyramid-1-yl)acetate in 150 ml of dry dichloromethane was added and the reaction mixture
20 stirred for an additional 30 minutes at room temperature. The solution was decanted from the residue and the residue washed with two 100 ml of dry diethyl ether. The organic solutions are combined, washed successively with two 200 ml portions of water and dried
25 over anhydrous sodium sulphate. Evaporation of the solvent under reduced pressure gives a residue which is crystallized from ethyl acetate to give methyl 2-(N-cyclohexyl-4-[(3-(ethan-1-on)-4-nitrophenyl)oxy]-butyramidyl)acetate.

30

Proceeding in a similar manner, the secondary alcohols of obtained by the reaction in Preparation 5 may be converted to their corresponding ketone using the above reagents but substituting the appropriate secondary alcohol for methyl 2-(N-cyclohexyl-4-(3-(1-hydroxyethyl)-
35 4-nitrophenyl)oxybutyramidyl)acetate.

PREPARATION 10

Preparation of methyl 2-(N-cyclohexyl-4-(2-carboxy-3-nitrophenyl)oxybutyramidyl)acetate and analogues as illustrated by Formula (11) in Reaction Scheme B.

5 To a solution of methyl 2-(N-cyclohexyl-4-(3-formyl-4-nitrophenyl)oxybutyramidyl)acetate (3.5 g) in dry pyridine (20 ml) under a blanket of nitrogen was added solid tetra-N-butylammonium permanganate portionwise over 1 hour. The reaction was stirred at
10 room temperature for 1 hour and was then poured into ethyl acetate/6 M hydrogen chloride (100 ml each). Solid sodium bisulfite was added to decolorize the solution and the layers were separated. The aqueous layer was washed with ethyl acetate (2 x 50 ml). The combined organic
15 layers were washed with 1 M HCl (3 x 50 ml) and brine (2 x 50 ml), dried, filtered and evaporated to give a syrup which foamed at high vacuum from dichloromethane to yield methyl 2-(N-cyclohexyl-4-(3-carboxy-4-nitrophenyl)-oxybutyramidyl)acetate.

20 Following this procedure, all of the aldehydes of Preparation 6 are converted to the corresponding acid.

PREPARATION 11

Reduction of the nitroacid compounds from
25 Preparation 10 to their anthranilic acid analog is carried out using the following reagents and conditions.

Methyl 2-(N-cyclohexyl-4-(3-carboxy-4-nitrophenyl)-oxybutyramidyl)acetate (78.7 g) was dissolved in absolute ethanol (750 ml) and hydrogenated at 60 psi over 10% Pd-C
30 (6 g) overnight. The catalyst was removed by filtration through a pad of Celite, and was thoroughly washed with additional ethanol (250 ml). The combined filtrates were thoroughly evaporated to give a thick syrup which crystallized from hexane/dichloromethane to afford methyl
35

2-(N-cyclohexyl-4-(3-carboxy-2-aminophenyl)-oxybutyramidyl)acetate.

Proceeding in a similar manner, but substituting the appropriate nitroacid for methyl 2-(N-cyclohexyl-4-(3-carboxy-4-nitrophenyl)oxybutyramidyl)acetate, nitroacids prepared as per Preparation 10 may be reduced to their corresponding amine.

PREPARATION 12

10 Ethyl 4-(2-oxo-1,2,3,5-tetrahydroimidazo-
 [2,1-b]quinazolin-7-yl)oxybutyrate

To a solution of 7-hydroxy-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one (2.6 g) made as per U. S. Patent No. 3,932,407 and ethyl 4-bromobutyrate (1.72 ml) 15 in 100 ml dimethylformamide was added 1.86g potassium carbonate. The reaction mixture was sealed under a blanket of nitrogen and heated to 100°C for 4 hours. The reaction mixture was cooled, poured into 100 ml of water, and the resulting precipitate collected by filtration. 20 Recrystallization from dimethylformamide-water gave 3.24g of ethyl 4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]-quinazolin-7-yl)oxybutyrate, m.p. 243-244°C.

PREPARATION 13

25 4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]-
 quinazolin-7-yl)oxybutyric acid

To a suspension of ethyl 4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyrate (65 g) in ethanol (1000 ml) was added 3N NaOH (100 ml) in 30 small portions. After 30 minutes at room temperature the reaction mixture was acidified with concentrated HCl. The resulting thick precipitate was collected by filtration and/or centrifugation and dried to give 4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin- 35 7-yl)oxybutyric acid (m.p. >300°C) quantitatively.

Esters prepared as per Preparation 12 above all may be converted to their corresponding acid by the foregoing method.

5

EXAMPLE 1

Methyl 2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetra-
hydroimidazo[2,1-b]quinazolin-7-yl)oxybutyr-
amid-yl)acetate

10 Methyl 2-(N-cyclohexyl-4-(3-formyl-4-nitrophenyl)-
oxybutyramidyl)acetate (12.5 g) was added to a solution
of glycine ethyl ester hydrochloride (44.7 g) and sodium
acetate (21 g) in methanol and stirred for 1 hour.
Sodium cyanoborohydride (1.21 g) was added and the
mixture was stirred for 30 minutes. The crude acetate
15 was isolated by filtering the solution, evaporating the
solvent, dissolving the residue in ethyl acetate which
was washed with dilute base and brine, dried and
evaporated to give a thick syrup. This syrup was taken
up in ethanol (300 ml) and reduced with 10% plaladium on
20 carbon (2 g). The catalyst was filtered out and the
combined filtrates treated sequentially with cyanogen
bromide (3.73 g) followed by ammonium hydroxide to yield
methyl-2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate,
25 m.p. 185-186°C. [Note: The melting point for this
compound was incorrectly given in the U.S. Patent
Application No. 580,409, filed February 15, 1984, as
207-208°C. In fact this latter 207-208°C melting point
is that of the corresponding amide compound (see below).]

30 Proceeding in the same manner but substituting the
appropriate ester or acetamide for methyl 2-(N-cyclohexyl-
4-(3-formyl-4-nitrophenyl)oxybutyamide)acetate all the
nitroaldehyde compounds of Preparation 6 or Preparation 7
are similarly converted to their corresponding
35

substituted 2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazoline-based alkyl ester or amide, examples
of which are:

- 5 methyl 2-(N-cyclohexylmethyl-4-(2-oxo-1,2,3,5-tetra-
hydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;
methyl 2-(N-methyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;
methyl 2-(N-hexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;
10 methyl 2-(N-phenyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;
methyl 2-(N-cyclohexyl-4-(2-oxo-5-methyl-1,2,3,5-
tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-
acetate;
15 methyl 2-(N-methyl-4-(2-oxo-3-methyl-1,2,3,5-tetra-
hydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;
hexyl 2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;
hexyl 2-(N-cyclohexylmethyl-4-(2-oxo-1,2,3,5-tetra-
20 hydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;
hexyl 2-(N-methyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;
hexyl 2-(N-hexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;
25 hexyl 2-(N-phenyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;
hexyl 2-(N-cyclohexyl-4-(2-oxo-5-methyl-1,2,3,5-
tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-
acetate;
30 hexyl 2-(N-methyl-4-(2-oxo-3-methyl-1,2,3,5-tetra-
hydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;
methyl 2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)hexanoate;

35

methyl 2-(N-cyclohexylmethyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-hexanoate;

5 methyl 2-(N-methyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)hexanoate;

methyl 2-(N-hexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)hexanoate;

10 methyl 2-(N-phenyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)hexanoate;

methyl 2-(N-cyclohexyl-4-(2-oxo-5-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-hexanoate;

15 methyl 2-(N-methyl-4-(2-oxo-3-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-hexanoate.

2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-acetamide, m.p. 207-208°C;

20 2-(N-cyclohexylmethyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-acetamide;

2-(N-methyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetamide;

25 2-(N-hexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetamide;

2-(N-phenyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetamide;

30 2-(N-cyclohexyl-4-(2-oxo-5-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-acetamide;

2-(N-methyl-4-(2-oxo-3-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-acetamide;

35

2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)N,N-dimethyl-
acetamide;

5 2-(N-cyclohexylmethyl-4-(2-oxo-1,2,3,5-tetra-
hydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)N,N-
dimethyl-acetamide;

2-(N-methyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]
quinazolin-7-yl)oxybutyramidyl)N,N-dimethyl-acetamide;

10 2-(N-hexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxybutyramidyl)N,N-dimethyl-
acetamide;

2-(N-phenyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]
quinazolin-7-yl)oxybutyramidyl)N,N-dimethyl-acetamide;

15 2-(N-cyclohexyl-4-(2-oxo-5-methyl-1,2,3,5-
tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-
N,N-dimethyl-acetamide;

2-(N-methyl-4-(2-oxo-3-methyl-1,2,3,5-tetra-
hydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-
N,N-dimethyl-acetamide;

20 2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)hexanamide;

2-(N-cyclohexylmethyl-4-(2-oxo-1,2,3,5-tetra-
hydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-
hexanamide;

25 2-(N-methyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]
quinazolin-7-yl)oxybutyramidyl)hexanamide;

2-(N-hexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxybutyramidyl)hexanamide;

30 2-(N-phenyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]
quinazolin-7-yl)oxybutyramidyl)hexanamide;

2-(N-cyclohexyl-4-(2-oxo-5-methyl-1,2,3,5-
tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-
hexanamide;

35

2-(N-methyl-4-(2-oxo-3-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-hexanamide;

5 2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)N-methyl-N-ethyl-acetamide;

2-(N-cyclohexylmethyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-N-methyl-N-ethyl-acetamide;

10 2-(N-methyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-7-yl)oxybutyramidyl)-N-methyl-N-ethyl-acetamide;

2-(N-hexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-7-yl)oxybutyramidyl)N-methyl-N-ethyl-acetamide;

15 2-(N-phenyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-7-yl)oxybutyramidyl)N-methyl-N-ethyl-acetamide;

2-(N-cyclohexyl-4-(2-oxo-5-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-N-methyl-N-ethyl-acetamide;

20 2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)N-methyl-acetamide;

2-(N-cyclohexylmethyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)N-methyl-acetamide;

2-(N-methyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-7-yl)oxybutyramidyl)N-methyl-acetamide;

2-(N-hexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-7-yl)oxybutyramidyl)N-methyl-acetamide;

30 2-(N-phenyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-7-yl)oxybutyramidyl)N-methyl-acetamide;

2-(N-cyclohexyl-4-(2-oxo-5-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-N-methyl-acetamide; and

35

2-(N-methyl-4-(2-oxo-3-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-N-methyl-acetamide.

5 2-(N-methyl-4-(2-oxo-3-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-N,N-dimethyl-acetamide;

EXAMPLE 2

10 2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramid-yl)acetic acid

A suspension of methyl 2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)-oxybutyramidyl)acetate (8.1 g) in 50 ml of methanol was
15 treated with 45 ml of 2N NaOH. The resulting solution was filtered to remove trace insoluble materials and then acidified to pH 5. The precipitated product was collected by filtration and dried to give
20 2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid, m.p. 194-195°C.

Proceeding in the same manner the esters prepared in Example 1 may be converted to their corresponding acid of
25 which the following are examples:

2-(N-cyclohexylmethyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;

2-(N-methyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;

30 2-(N-hexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;

2-(N-phenyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;

35 2-(N-cyclohexyl-4-(2-oxo-5-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;

- 2-(N-methyl-4-(2-oxo-3-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;
2-(N-cyclohexyl-4-(2-oxo-3-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;
5 2-(N-cyclohexyl-4-(2-oxo-6-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;
2-(N-cyclohexyl-4-(2-oxo-6-methoxy-1,2,3,5-tetra-
hydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramid-
yl)acetic acid;
10 2-(N-cyclohexyl-4-(2-oxo-6-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;
2-(N-methyl-4-(2-oxo-6-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;
2-(N-benzyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
15 [2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;
2-(N-cyclohexylbutyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;
2-(N-cyclooctyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;
20 2-(N-cyclopentyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;
2-(N-cyclopentyl-4-(2-oxo-6-chloro-1,2,3,5-
tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramid-
yl)acetic acid;
25 2-(N-cyclopentylmethyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;
2-(N-diphenylmethyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;
2-(N-methyl-4-(2-oxo-9-methyl-1,2,3,5-tetrahydro-
30 imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;
2-(N-hexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;
2-(N-(4-chlorobenzyl)-4-(2-oxo-1,2,3,5-tetrahydro
imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;
35

- 2-(N-(4-methoxybenzyl)-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid;
2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-6-yl)oxybutyramidyl)acetic acid;
5 2-(N-cyclohexylbutyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxybutyramidyl)acetic acid;
2-(N-cyclohexylmethyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxybutyramidyl)acetic acid;
10 2-(N-phenyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-6-yl)oxybutyramidyl)acetic acid;
2-(N-cyclohexyl-4-(2-oxo-7-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxybutyramidyl)acetic acid;
2-(N-cyclohexyl-4-(2-oxo-7-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxybutyramidyl)acetic acid;
15 2-(N-cyclohexyl-4-(2-oxo-9-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxybutyramidyl)acetic acid;
2-(N-benzyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]-
6-oxoquinazolin-6-yl)oxybutyramidyl)acetic acid;
2-(N-cyclopentyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
20 [2,1-b]quinazolin-6-yl)oxybutyramidyl)acetic acid;
2-(N-cyclopentylmethyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxybutyramidyl)acetic acid;
2-(N-diphenylmethyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxybutyramidyl)acetic acid;
25 2-(N-(4-chlorobenzyl)-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxybutyramidyl)acetic acid;
2-(N-(4-methoxybenzyl)-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxybutyramidyl)acetic acid;
2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
30 [2,1-b]quinazolin-8-yl)oxybutyramidyl)acetic acid;
2-(N-cyclohexyl-4-(2-oxo-6-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxybutyramidyl)acetic acid;
2-(N-cyclohexylmethyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxybutyramidyl)acetic acid;
35

- 2-(N-cyclohexyl-4-(2-oxo-6-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxybutyramidyl)acetic acid;
2-(N-cyclohexylbutyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxybutyramidyl)acetic acid;
5 2-(N-methyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-8-yl)oxybutyramidyl)acetic acid;
2-(N-cyclohexyl-4-(2-oxo-7-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxybutyramidyl)acetic acid;
2-(N-cyclohexyl-4-(2-oxo-7-methyl-1,2,3,5-tetrahydro-
10 imidazo[2,1-b]quinazolin-8-yl)oxybutyramidyl)acetic acid;
2-(N-cyclohexyl-4-(2-oxo-9-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxybutyramidyl)acetic acid;
2-(N-benzyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-8-yl)oxybutyramidyl)acetic acid;
15 2-(N-cyclopentyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-8-yl)oxybutyramidyl)acetic acid;
2-(N-cyclopentylbutyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxybutyramidyl)acetic acid;
2-(N-diphenylmethyl-4-(2-oxo-1,2,3,5-tetrahydro-
20 imidazo[2,1-b]quinazolin-8-yl)oxybutyramidyl)acetic acid;
2-(N-(4-chlorobenzyl)-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxybutyramidyl)acetic acid;
2-(N-(4-methoxybenzyl)-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxybutyramidyl)acetic acid;
25 2-(N-cyclopentyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-9-yl)oxybutyramidyl)acetic acid;
2-(N-phenyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-9-yl)oxybutyramidyl)acetic acid;
2-(N-cyclohexyl-4-(2-oxo-6-chloro-1,2,3,5-tetrahydro-
30 imidazo[2,1-b]quinazolin-9-yl)oxybutyramidyl)acetic acid;
2-(N-cyclohexylbutyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-9-yl)oxybutyramidyl)acetic acid;
2-(N-methyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-9-yl)oxybutyramidyl)acetic acid;
35

- 2-(N-hexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-9-yl)oxybutyramidyl)acetic acid;
2-(N-benzyl-4-(2-oxy-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-9-yl)oxybutyramidyl)acetic acid;
5 2-(N-cyclopentyl-4-(2-oxy-6-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-9-yl)oxybutyramidyl)acetic acid;
2-(N-diphenylmethyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-9-yl)oxybutyramidyl)acetic acid;
2-(N-cyclohexyl-7-(2-oxo-1,2,3,5-tetrahydroimidazo-
10 [2,1-b]quinazolin-7-yl)oxyheptanamidyl)acetic acid;
2-(N-cyclohexylmethyl-7-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxyheptanamidyl)acetic acid;
2-(N-phenyl-7-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxyheptanamidyl)acetic acid;
15 2-(N-methyl-7-(2-oxo-5-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxyheptanamidyl)acetic acid;
2-(N-phenyl-7-(2-oxo-3-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxyheptanamidyl)acetic acid;
2-(N-cyclohexyl-7-(2-oxo-6-chloro-1,2,3,5-tetrahydro-
20 imidazo[2,1-b]quinazolin-7-yl)oxyheptanamidyl)acetic acid;
2-(N-cyclohexyl-7-(2-oxo-3-methyl-6-chloro-1,2,3,5-
tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxy-
heptanamidyl)acetic acid;
2-(N-cyclopentylbutyl-7-(2-oxo-1,2,3,5-tetrahydro-
25 imidazo[2,1-b]quinazolin-7-yl)oxyheptanamidyl)acetic acid;
2-(N-cyclohexyl-7-(2-oxo-6-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxyheptanamidyl)acetic acid;
2-(N-hexyl-7-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxyheptanamidyl)acetic acid;
30 2-(N-cyclohexyl-7-(2-oxo-6-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxyheptanamidyl)acetic acid;
2-(N-cyclohexyl-7-(2-oxo-6-methoxy-1,2,3,5-tetra-
hydroimidazo[2,1-b]quinazolin-7-yl)oxyheptanamidyl)-
acetic acid;
35

- 2-(N-benzyl-7-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxyheptanamidyl)acetic acid;
2-(N-cyclohexyl-7-(2-oxo-6-methoxy-1,2,3,5-tetra-
hydroimidazo[2,1-b]quinazolin-7-yl)oxyheptanamidyl)-
5 acetic acid;
2-(N-cyclopentyl-7-(2-oxo-6-chloro-1,2,3,5-tetra-
hydroimidazo[2,1-b]quinazolin-7-yl)oxyheptanamidyl)-
acetic acid;
2-(N-diphenylmethyl-7-(2-oxo-1,2,3,5-tetrahydro-
10 imidazo[2,1-b]quinazolin-7-yl)oxyheptanamidyl)acetic acid;
2-(N-(4-chlorobenzyl)-7-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxyheptanamidyl)acetic acid;
2-(N-(4-methoxybenzyl)-7-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxyheptanamidyl)acetic acid;
15 2-(N-cyclohexylbutyl-7-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxyheptanamidyl)acetic acid;
2-(N-phenyl-7-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-6-yl)oxyheptanamidyl)acetic acid;
2-(N-cyclohexyl-7-(2-oxo-7-chloro-1,2,3,5-tetrahydro-
20 imidazo[2,1-b]quinazolin-6-yl)oxyheptanamidyl)acetic acid;
2-(N-cyclohexyl-7-(2-oxo-7-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxyheptanamidyl)acetic acid;
2-(N-cyclohexyl-7-(2-oxo-9-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxyheptanamidyl)acetic acid;
25 2-(N-benzyl-7-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-6-yl)oxyheptanamidyl)acetic acid;
2-(N-cyclopentyl-7-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxyheptanamidyl)acetic acid;
2-(N-cyclopentylbutyl-7-(2-oxo-1,2,3,5-tetrahydro-
30 imidazo[2,1-b]quinazolin-6-yl)oxyheptanamidyl)acetic acid;
2-(N-(4-chlorobenzyl)-7-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxyheptanamidyl)acetic acid;
2-(N-(4-methoxybenzyl)-7-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxyheptanamidyl)acetic acid;
35

- 2-(N-cyclohexyl-7-(2-oxo-6-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxyheptanamidyl)acetic acid;
2-(N-cyclohexyl-7-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxyheptanamidyl)acetic acid;
5 2-(N-cyclohexylbutyl-7-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxyheptanamidyl)acetic acid;
2-(N-cyclohexyl-7-(2-oxo-6-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxyheptanamidyl)acetic acid;
10 2-(N-phenyl-7-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-8-yl)oxyheptanamidyl)acetic acid;
2-(N-cyclohexyl-7-(2-oxo-7-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxyheptanamidyl)acetic acid;
2-(N-cyclohexyl-7-(2-oxo-7-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxyheptanamidyl)acetic acid;
15 2-(N-benzyl-7-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-8-yl)oxyheptanamidyl)acetic acid;
2-(N-cyclopentyl-7-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxyheptanamidyl)acetic acid;
2-(N-cyclopentylmethyl-7-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxyheptanamidyl)acetic acid;
20 2-(N-cyclopentylbutyl-7-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxyheptanamidyl)acetic acid;
2-(N-diphenylmethyl-7-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxyheptanamidyl)acetic acid;
25 2-(N-phenyl-7-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-8-yl)oxyheptanamidyl)acetic acid;
2-(N-(4-chlorobenzyl)-7-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxyheptanamidyl)acetic acid;
2-(N-phenyl-7-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-9-yl)oxyheptanamidyl)acetic acid;
30 2-(N-cyclohexylbutyl-7-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-9-yl)oxyheptanamidyl)acetic acid;
2-(N-cyclohexyl-7-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-9-yl)oxyheptanamidyl)acetic acid;
35

- 2-(N-benzyl-7-(2-oxy-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-9-yl)oxyheptanamidyl)acetic acid;
2-(N-cyclopentyl-7-(2-oxy-6-methyl-1,2,3,5-tetra-
hydroimidazo[2,1-b]quinazolin-9-yl)oxyheptanamidyl)-
5 acetic acid;
2-(N-cyclohexyl-2-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxyacetamidyl)acetic acid;
2-(N-phenyl-2-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxyacetamidyl)acetic acid;
10 2-(N-cyclohexylmethyl-2-(2-oxo-5-methyl-1,2,3,5-
tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxyacetamidyl)-
acetic acid;
2-(N-phenyl-2-(2-oxo-3-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxyacetamidyl)acetic acid;
15 2-(N-cyclohexyl-2-(2-oxo-6-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxyacetamidyl)acetic acid;
2-(N-methyl-2-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]-
quinazolin-7-yl)oxyacetamidyl)acetic acid;
2-(N-hexyl-2-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]-
20 quinazolin-7-yl)oxyacetamidyl)acetic acid;
2-(N-cyclohexyl-2-(2-oxo-3-methyl-6-chloro-1,2,3,5-
tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxyacetamidyl)-
acetic acid;
2-(N-cyclopentylbutyl-2-(2-oxo-1,2,3,5-tetrahydro-
25 imidazo[2,1-b]quinazolin-7-yl)oxyacetamidyl)acetic acid;
2-(N-cyclohexyl-2-(2-oxo-6-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxyacetamidyl)acetic acid;
2-(N-cyclopentyl-2-(2-oxo-6-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxyacetamidyl)acetic acid;
30 2-(N-phenyl-2-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-6-yl)oxyacetamidyl)acetic acid;
2-(N-cyclohexyl-2-(2-oxo-7-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxyacetamidyl)acetic acid;
2-(N-benzyl-2-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]-
35 quinazolin-6-yl)oxyacetamidyl)acetic acid;

- 2-(N-cyclohexyl-2-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-8-yl)oxyacetamidyl)acetic acid;
2-(N-cyclohexylbutyl-2-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxyacetamidyl)acetic acid;
5 2-(N-phenyl-2-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-8-yl)oxyacetamidyl)acetic acid;
2-(N-cyclopentyl-2-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-8-yl)oxyacetamidyl)acetic acid;
2-(N-cyclopentylmethyl-2-(2-oxo-1,2,3,5-tetrahydro-
10 imidazo[2,1-b]quinazolin-8-yl)oxyacetamidyl)acetic acid;
2-(N-cyclopentyl-2-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-9-yl)oxyacetamidyl)acetic acid;
2-(N-phenyl-2-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-9-yl)oxyacetamidyl)acetic acid;
15 2-(N-cyclohexyl-2-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-9-yl)oxyacetamidyl)acetic acid;
2-(N-methyl-2-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]-
quinazolin-9-yl)oxyacetamidyl)acetic acid;
2-(N-cyclohexylmethyl-5-(2-oxo-1,2,3,5-tetrahydro-
20 imidazo[2,1-b]quinazolin-7-yl)oxypentanamidyl)acetic acid;
2-(N-phenyl-5-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]-
quinazolin-7-yl)oxypentanamidyl)acetic acid;
2-(N-cyclohexylmethyl-5-(2-oxo-5-methyl-1,2,3,5-tetra-
hydroimidazo[2,1-b]quinazolin-7-yl)oxypentanamidyl)-
25 acetic acid;
2-(N-phenyl-5-(2-oxo-3-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxypentanamidyl)acetic acid;
2-(N-cyclohexyl-5-(2-oxo-6-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxypentanamidyl)acetic acid;
30 2-(N-cyclohexyl-5-(2-oxo-3-methyl-6-chloro-1,2,3,5-
tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxypentanamidyl)-
acetic acid;
2-(N-cyclohexyl-5-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxypentanamidyl)acetic acid;
35

- 2-(N-cyclopentylbutyl-5-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxypentanamidyl)acetic acid;
2-(N-cyclohexyl-5-(2-oxo-6-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxypentanamidyl)acetic acid;
5 2-(N-cyclohexyl-5-(2-oxo-6-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxypentanamidyl)acetic acid;
2-(N-cyclohexyl-5-(2-oxo-6-methoxy-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxypentanamidyl)acetic acid;
10 2-(N-benzyl-5-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxypentanamidyl)acetic acid;
2-(N-cyclohexylbutyl-5-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxypentanamidyl)acetic acid;
2-(N-cyclopentyl-5-(2-oxo-6-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxypentanamidyl)acetic acid;
15 2-(N-diphenylmethyl-5-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxypentanamidyl)acetic acid;
2-(N-n-hexyl-5-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxypentanamidyl)acetic acid;
20 2-(N-phenyl-5-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]-
quinazolin-7-yl)oxypentanamidyl)acetic acid;
2-(N-benzyl-5-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]-
quinazolin-7-yl)oxypentanamidyl)acetic acid;
2-(N-(4-chlorobenzyl)-5-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxypentanamidyl)acetic acid;
25 2-(N-(4-methoxybenzyl)-5-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxypentanamidyl)acetic acid;
2-(N-cyclohexylbutyl-5-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxypentanamidyl)acetic acid;
30 2-(N-cyclohexyl-5-(2-oxo-7-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxypentanamidyl)acetic acid;
2-(N-cyclohexyl-5-(2-oxo-7-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxypentanamidyl)acetic acid;
2-(N-cyclohexyl-5-(2-oxo-9-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxypentanamidyl)acetic acid;
35

- 2-(N-cyclopentyl-5-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-6-yl)oxypentanamidyl)acetic acid;
2-(N-(4-chlorobenzyl)-5-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxypentanamidyl)acetic acid;
5 2-(N-(4-methoxybenzyl)-5-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxypentanamidyl)acetic acid;
2-(N-cyclohexyl-5-(2-oxo-6-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxypentanamidyl)acetic acid;
2-(N-cyclohexyl-5-(2-oxo-6-methoxy-1,2,3,5-tetrahydro-
10 imidazo[2,1-b]quinazolin-8-yl)oxypentanamidyl)acetic acid;
2-(N-cyclohexylbutyl-5-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxypentanamidyl)acetic acid;
2-(N-cyclohexyl-5-(2-oxo-6-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxypentanamidyl)acetic acid;
15 2-(N-phenyl-5-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-8-yl)oxypentanamidyl)acetic acid;
2-(N-cyclohexyl-5-(2-oxo-7-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxypentanamidyl)acetic acid;
2-(N-cyclohexyl-5-(2-oxo-7-methyl-1,2,3,5-tetrahydro-
20 imidazo[2,1-b]quinazolin-8-yl)oxypentanamidyl)acetic acid;
2-(N-benzyl-5-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-8-yl)oxypentanamidyl)acetic acid;
2-(N-cyclopentyl-5-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-8-yl)oxypentanamidyl)acetic acid;
25 2-(N-cyclopentylmethyl-5-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxypentanamidyl)acetic acid;
2-(N-cyclopentylbutyl-5-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxypentanamidyl)acetic acid;
2-(N-diphenylmethyl-5-(2-oxo-1,2,3,5-tetrahydro-
30 imidazo[2,1-b]quinazolin-8-yl)oxypentanamidyl)acetic acid;
2-(N-phenyl-5-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-9-yl)oxypentanamidyl)acetic acid;
2-(N-cyclohexylbutyl-5-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-9-yl)oxypentanamidyl)acetic acid;
35

- 2-(N-cyclohexyl-5-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-9-yl)oxypentanamidyl)acetic acid;
2-(N-methyl-5-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-9-yl)oxypentanamidyl)acetic acid;
5 2-(N-benzyl-5-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-9-yl)oxypentanamidyl)acetic acid;
2-(N-cyclopentyl-5-(2-oxo-6-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-9-yl)oxypentanamidyl)acetic acid;
2-(N-cyclohexyl-6-(2-oxo-1,2,3,5-tetrahydroimidazo-
10 [2,1-b]quinazolin-7-yl)oxyhexanamidyl)acetic acid;
2-(N-cyclohexylmethyl-6-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxyhexanamidyl)acetic acid;
2-(N-phenyl-6-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxyhexanamidyl)acetic acid;
15 2-(N-methyl-6-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxyhexanamidyl)acetic acid;
2-(N-phenyl-6-(2-oxo-3-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxyhexanamidyl)acetic acid;
2-(N-cyclohexyl-6-(2-oxo-6-chloro-1,2,3,5-tetrahydro-
20 imidazo[2,1-b]quinazolin-7-yl)oxyhexanamidyl)acetic acid;
2-(N-cyclohexyl-6-(2-oxo-3-methyl-6-chloro-1,2,3,5-
tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxyhexanamidyl)-
acetic acid;
2-(N-cyclohexylbutyl-6-(2-oxo-1,2,3,5-tetrahydro-
25 imidazo[2,1-b]quinazolin-7-yl)oxyhexanamidyl)acetic acid;
2-(N-cyclohexyl-6-(2-oxo-6-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxyhexanamidyl)acetic acid;
2-(N-cyclohexyl-6-(2-oxo-6-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxyhexanamidyl)acetic acid;
30 2-(N-cyclohexyl-6-(2-oxo-6-methoxy-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxyhexanamidyl)acetic acid;
2-(N-benzyl-6-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxyhexanamidyl)acetic acid;
2-(N-cyclohexyl-6-(2-oxo-6-methoxy-1,2,3,5-tetrahydro-
35 imidazo[2,1-b]quinazolin-7-yl)oxyhexanamidyl)acetic acid;

- 2-(N-diphenylmethyl-6-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxyhexanamidyl)acetic acid;
2-(N-n-hexyl-6-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxyhexanamidyl)acetic acid;
5 2-(N-phenyl-6-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]-
quinazolin-7-yl)oxyhexanamidyl)acetic acid;
2-(N-(4-chlorobenzyl)-6-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxyhexanamidyl)acetic acid;
2-(N-(4-methoxybenzyl)-6-(2-oxo-1,2,3,5-tetrahydro-
10 imidazo[2,1-b]quinazolin-7-yl)oxyhexanamidyl)acetic acid;
2-(N-cyclohexylbutyl-6-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxyhexanamidyl)acetic acid;
2-(N-phenyl-6-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-6-yl)oxyhexanamidyl)acetic acid;
15 2-(N-cyclohexyl-4-(2-oxo-7-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxyhexanamidyl)acetic acid;
2-(N-cyclohexyl-4-(2-oxo-7-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxyhexanamidyl)acetic acid;
2-(N-cyclohexyl-6-(2-oxo-9-chloro-1,2,3,5-tetrahydro-
20 imidazo[2,1-b]quinazolin-6-yl)oxyhexanamidyl)acetic acid;
2-(N-benzyl-6-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]-
quinazolin-6-yl)oxyhexanamidyl)acetic acid;
2-(N-cyclopentyl-6-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-6-yl)oxyhexanamidyl)acetic acid;
25 2-(N-cyclopentylbutyl-6-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxyhexanamidyl)acetic acid;
2-(N-4-chlorobenzyl-6-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-6-yl)oxyhexanamidyl)acetic acid;
2-(N-4-methoxybenzyl-6-(2-oxo-1,2,3,5-tetrahydro-
30 imidazo[2,1-b]quinazolin-6-yl)oxyhexanamidyl)acetic acid;
2-(N-cyclohexyl-6-(2-oxo-6-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxyhexanamidyl)acetic acid;
2-(N-cyclohexyl-6-(2-oxo-6-methoxy-1,2,3,5-tetrahydro-
35 imidazo[2,1-b]quinazolin-8-yl)oxyhexanamidyl)acetic acid;

- 2-(N-cyclohexylbutyl-6-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxyhexanamidyl)acetic acid;
2-(N-cyclohexyl-6-(2-oxo-6-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxyhexanamidyl)acetic acid;
5 2-(N-phenyl-6-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-8-yl)oxyhexanamidyl)acetic acid;
2-(N-cyclohexyl-6-(2-oxo-7-chloro-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxyhexanamidyl)acetic acid;
2-(N-cyclohexyl-6-(2-oxo-7-methyl-1,2,3,5-tetrahydro-
10 imidazo[2,1-b]quinazolin-8-yl)oxyhexanamidyl)acetic acid;
2-(N-benzyl-6-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]-
quinazolin-8-yl)oxyhexanamidyl)acetic acid;
2-(N-cyclopentyl-6-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-8-yl)oxyhexanamidyl)acetic acid;
15 2-(N-cyclopentylmethyl-6-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxyhexanamidyl)acetic acid;
2-(N-cyclopentylbutyl-6-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxyhexanamidyl)acetic acid;
2-(N-diphenylmethyl-6-(2-oxo-1,2,3,5-tetrahydro-
20 imidazo[2,1-b]quinazolin-8-yl)oxyhexanamidyl)acetic acid;
2-(N-(4-chlorobenzyl)-6-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-8-yl)oxyhexanamidyl)acetic acid;
2-(N-cyclohexyl-6-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-9-yl)oxyhexanamidyl)acetic acid;
25 2-(N-cyclopentyl-6-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-9-yl)oxyhexanamidyl)acetic acid;
2-(N-phenyl-6-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-9-yl)oxyhexanamidyl)acetic acid;
2-(N-cyclohexylbutyl-6-(2-oxo-1,2,3,5-tetrahydro-
30 imidazo[2,1-b]quinazolin-9-yl)oxyhexanamidyl)acetic acid;
2-(N-benzyl-6-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-9-yl)oxyhexanamidyl)acetic acid; and
2-(N-cyclopentyl-6-(2-oxo-6-methyl-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-9-yl)oxyhexanamidyl)acetic acid.
35

EXAMPLE 3

Methyl 2-(N-cyclohexyl-4-(2-oxo-3-D-hydroxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)-oxybutyramidyl)acetate

5 To a solution of methyl 2-(N-cyclohexyl-4-(3-formyl-4-nitrophenyl)oxybutyramid-1-yl)acetate (25 mmol),
D-serine methyl ester hydrochloride (7.0 g, 50 mmol) and
3A molecular sieves (5.0 g) in methanol (75 ml) was
added D-serine methyl ester (20.6 g, 200 mmol). After
10 allowing the solution to stir for 5 minutes at room
temperature, sodium cyanoborohydride (0.95 g, 15 mmol)
was added in one amount. The reaction mixture was
allowed to stir at room temperature for 3-4 hours. The
reaction solution was then filtered to remove
15 precipitated solids and molecular sieves, and the
methanol was removed by evaporation. The residue was
dissolved in ethyl acetate (300 ml) and was washed with
saturated sodium bicarbonate (2 x 100 ml) and brine
(2 x 100 ml). The organic extract was dried, filtered
20 and evaporated to give a thick syrup. The thick syrupy
residue was dissolved in absolute ethanol (100 ml) and
hydrogenated over 10% Pd-C (1.0 g) until uptake of
hydrogen ceased, approximately 4 hours. The catalyst was
removed by filtration through a pad of Celite, and pad
25 was washed clean with absolute ethanol (50 ml). The
combined filtrates were treated with cyanogen bromide
(3.20 g, 30 mmol), and the resulting solution maintained
at a reflux for 16 hours. Upon cooling, the ethanol was
removed, and the residue was dissolved in ethanol
30 (100 ml) and treated with ammonium hydroxide (25 ml) and
stirred for 2 hours at room temperature. The product was
precipitated from this mixture and further purified by
filtration and a water wash, dried, yielding methyl

35

2-(N-cyclohexyl-4-(2-oxo-3-D-hydroxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramid-1-yl)acetate.

Proceeding in a like manner but substituting
5 D-serine methyl ester with other appropriate optically active α -aminocarboxylic acid esters, there may be prepared the following exemplary optical isomers of Formula I:

10 methyl 2-(N-cyclohexyl-4-(2-oxo-3-L-hydroxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;

methyl 2-(N-cyclohexyl-4-(2-oxo-3-L-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-acetate;

15 methyl 2-(N-cyclohexyl-4-(2-oxo-3-D-m-1-yl)acetat-ethyl-1,2,3,5-t-1-yl)acetatetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;

methyl 2-(N-cyclohexyl-4-(2-oxo-3-D-methyl-1,2,3,5-t-1-yl)acetatetrahydroimidazo[2,1-b]quinazolin-7-yl)oxy-
20 butyramidyl)acetate;

methyl 2-(N-cyclohexyl-4-(2-oxo-3-L-ethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-acetate;

25 methyl 2-(N-cyclohexyl-4-(2-oxo-3-D-(1-hydroxyethyl)-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;

methyl 2-(N-cyclohexyl-4-(2-oxo-3-L-(1-hydroxyethyl)-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;

30 methyl 2-(N-cyclohexyl-4-(2-oxo-3-D-isopropyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;

methyl 2-(N-cyclohexyl-4-(2-oxo-3-L-isopropyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxy-
35 butyramidyl)acetate;

methyl 2-(N-cyclohexyl-4-(2-oxo-3-D-benzyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;

5 methyl 2-(N-cyclohexyl-4-(2-oxo-3-L-benzyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;

methyl 2-(N-cyclohexyl-4-(2-oxo-3-D-phenyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;

10 methyl 2-(N-cyclohexyl-4-(2-oxo-3-L-phenyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;

methyl 2-(N-cyclohexyl-4-(2-oxo-3-D-acetoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;

methyl 2-(N-cyclohexyl-4-(2-oxo-3-L-acetoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate;

20 methyl 2-(N-cyclohexyl-4-(2-oxo-3-D-carbamoylmethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate; and

methyl 2-(N-cyclohexyl-4-(2-oxo-3-L-carbamoylmethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate.

25 These compounds are converted to their acetic acid analogs by the saponification procedure set out in Example 2 above.

EXAMPLE 4

30 Methyl 2-(N-cyclohexyl-4-(2,5-dioxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate

To a suspension of methyl 5-(4-(N-cyclohexyl-N-methylacetoxymethyl)oxyanthranilic acid (0.05 g, 1.5 mmol) in ethanol (10 ml) was added an ethanolic

35

solution of freshly prepared 2-methylthiohydantoin (3.4 mmol). The dark mixture was heated and maintained at reflux for 3 hours. The reaction mixture was then cooled, diluted with water and triturated to give methyl
5 2-(N-cyclohexyl-4-(2,5-dioxo-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate.

This and other analogous compounds are then converted to the free acid by the procedure set out in Example 2.

10

EXAMPLE 5

Methyl 2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydro-imadazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate

To a solution of 4-(2-oxo-1,2,3,5-tetrahydro-
15 imadazo[2,1-b]quinazolin-7-yl)oxybutyric acid (3.44 g) and 1-hydroxybenzotriazole (1.5g) in 25 ml dry dimethylformamide was added diisopropylcarbodiimide (1.39 g). After one hour at room temperature, a solution of methyl N-cyclohexylglycinate (1.56 ml) and 1.32 ml of
20 N-methylmorpholine in 10 ml of dry dimethylformamide was added. The resulting solution was stirred overnight at room temperature and was then diluted with water. The resulting precipitate was collected and dried over phosphorous pentoxide to give methyl 2-(N-cyclohexyl-
25 4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)-oxybutyramid-1-yl)acetate.

Proceeding in a similiar manner, all oxyalkyl acids prepared as per Preparation 13 are converted to their corresponding ester.

30 These esters are then converted to the free acid by the procedure set out in Example 2.

35

EXAMPLE 6

Into a solution of the ethyl ester (3.2 g, 10 mmol) prepared in Preparation 12 and tetra-N-butylammonium bromide (6.44 g, 20 mmol) in DMF (100 ml) was added
5 aqueous KOH (1.5 g in 5 ml H₂O), stirred overnight at room temperature. Molecular sieves (3Å, 25 g) were added, and the mixture was left to stand 3 days. methyl N-cyclohexylglycinate (2.6 ml, 20 mmol) and
10 bis(o-nitrophenyl)phenylphosphonate (10 g, 25 mmol) were added, and the mixture was shaken for 24 hours. The mixture was filtered through Celite, and the DMF was evaporated at high vacuum. The residue was triturated with 5% aqueous ammonium hydroxide and ethanol (1:1) to
15 give a precipitate, collected by filtration, washed with ethanol and dried to give methyl N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate.

EXAMPLE 7

20 The compounds of Formula I wherein R₄ is hydrogen are converted to those wherein R₄ is alkyl of 1 to 6 carbon atoms, benzyl or hydroxy lower alkyl by the following procedure.

To a solution of methyl 2-(N-cyclohexyl-
25 4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate in dry dimethylformamide was added sodium hydride (1.05 equivalents). The mixture was stirred at 60°C for 30 minutes to give a homogeneous solution. 1-Bromobutane (1.1 equivalents) was added via
30 a syringe after which the mixture was evaporated. The residue was dissolved in ethyl acetate and washed with saturated brine, dried and filtered. Evaporation of the solvent afforded methyl 2-(N-cyclohexyl-4-(1-butyl-2-dioxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-
35 7-yl)oxybutyramidyl)acetate.

EXAMPLE 8Conversion of Free Base to Salt

A two-fold stoichiometric excess of 3% hydrogen chloride in methanol is added to a solution of 1.0 g. of methyl 2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydro-
5 imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate in 20 ml methanol. Diethyl ether is added until precipitation is complete. The product is filtered, washed with ether, air dried and recrystallized to give
10 methyl 2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydro-imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate hydrochloride.

EXAMPLE 9Conversion of Salt to Free Base

1.0 g of methyl 2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)-
acetate HCl suspended in 50 ml of ether is stirred with one equivalent of dilute aqueous potassium carbonate
20 solution until the salt is completely dissolved. The organic layer is then separated, washed twice with water, dried over magnesium sulfate and evaporated to yield methyl 2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate as
25 the free base.

EXAMPLE 10

Compounds of the present invention, either the free base or a pharmaceutically acceptable salt, may be orally
30 administered to a subject as a tablet. While the active ingredient may comprise anywhere between 5 and 90 percent of the formulation that percentage preferably will be an amount which will cause to be delivered to the subject, the active ingredient in an amount of between 20 mg and
35 100 mg per tablet. Following is a representative tablet

formulation in which the active ingredient is methyl
N-cyclehexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate. However,
the formulation profile given below may be used to
formulate a tablet for any of the compounds represented
by Formula I.

	<u>Ingredients</u>	<u>Quantity per tablet, mgs.</u>
	Active ingredient	25
	cornstarch	20
10	lactose, spray-dried	153
	magnesium stearate	2

The above ingredients are thoroughly mixed and
pressed into single scored tablets.

15

EXAMPLE 11

An alternative oral dosage form is to fill hard
shell gelatin capsules with a powder containing the
active ingredient in the desired amount. Using the
active ingredient mentioned in Example 6 above, the acid
addition salts, or any other compound according to
Formula I there may be prepared an exemplary hard shell
gelatin capsule formulation using the following
ingredients

	<u>Ingredients</u>	<u>Quantity per tablet, mgs.</u>
25	Active ingredient	100
	lactose, spray-dried	148
	magnesium stearate	2

The above ingredients are mixed and introduced into
a hard-shell gelatin capsule.

30

EXAMPLE 12

Alternatively, compounds of the present invention
may be prepared as a suspension for oral administration.

35

Any of the compounds of Formula I, either in free form or as the acid addition salt, may be used in this formulation.

5 An oral suspension is prepared having the following composition:

Ingredients

Active ingredient	0.1 g
fumaric acid	0.5 g
sodium chloride	2.0 g
10 methyl paraben	0.1 g
granulated sugar	25.5 g
sorbitol (70% solution)	12.85 g
Veegum K (Vanderbilt Co.)	1.0 g
flavoring	0.035 ml
15 colorings	0.5 mg
distilled water	q.s. to 100 ml

EXAMPLE 13

20 Cyclic AMP phosphodiesterase activity and inhibition of platelet aggregation were determined as follows.

Cyclic AMP phosphodiesterase assay

The inhibition of cyclic AMP phosphodiesterase activity by the subject compounds was assayed by the
25 method of Filburn and Karn, Analyt. Biochem., 52:505-516 (1973), using 1 μ M cyclic AMP as the substrate. Human platelet cyclic AMP phosphodiesterase was obtained from human donors. Platelets were isolated and washed by centrifugation, the membranes ruptured by a sequential
30 freeze-thaw procedure and hypotonic lysis and the soluble enzyme isolated by high speed centrifugation. The enzyme was stored in aliquots at -20°C.

Platelet Aggregation

35 Blood was collected into evacuated tubes containing sodium citrate (30 mM). Platelet rich plasma was

collected after centrifugation. Aggregation was followed by a turbidimetric procedure described by G. V. R. Born, J. Physiol., Lond., 162:67P-68P (1962).

5 Inhibition of cyclic AMP phosphodiesterase data (relative to theophylline) are presented in Table I below. This table contains the IC_{50} values for human platelet phosphodiesterase and IC_{25} values for rat heart phosphodiesterase.

10

15

20

25

30

35

TABLE I

INHIBITION OF CYCLIC AMP PHOSPHODIESTERASE
IN HUMAN PLATELETS AND ANIMAL HEART

5	Compound ^c	Human Platelet IC ₅₀ [nM]	Heart IC ₂₅ [nM]	Relative Potency ^c
10	methyl 2-(N-cyclohexyl-4-(2-oxo- (1,2,3,5-tetrahydroimidazo[2,1-b]- quinazolin-7-yl)oxybutyramidyl)- yl)acetate	2.0	10.0 ^a	135,000
	2-(N-cyclohexyl-4-(2-oxo- -1,2,3,5-tetrahydroimidazo[2,1-b]- quinazolin-7-yl)oxybutyramidyl)- acetic acid	5.0	100 ^b	54,000
15	2-(N-cyclohexyl-4-(2-oxo- 1,2,3,5-tetrahydroimidazo[2,1-b]- quinazolin-7-yl)oxybutyramidyl)- acetamide	11.0	100 ^a	24,500

a. Soluble dog heart PDE

b. Soluble rat heart PDE

20 c. Potency relative to theophylline which is assigned a value of 1 on
human platelet phosphodiesterase.

25

30

7490K

24250-FF

35

EXAMPLE 14Inotropic Activity of the Compounds
of the Present Invention

Mongrel dogs were anesthetized i.v. with 35 mg/kg
5 sodium pentobarbital and supplemented as needed. Blood
pressure was measured with a Statham pressure transducer
via a cannula inserted from a femoral artery into the
abdominal aorta. Heart rate was recorded by a
cardiotachometer from a lead II electrocardiogram. Right
10 ventricular contractile force was recorded from a
Walton-Brodie strain gauge sutured to the right ventricle
following a midsternal thoractomy. A Harvard respirator
was used to ventilate the dogs with room air through an
endotracheal tube. Each dog was bilaterally
15 vagotomized. Following a midline laparotomy, a cannula
was sutured into the duodenum for intraduodenal
administration of test compound. A femoral vein was
cannulated for administration of isoproterenol. All data
were recorded on a Beckman R611 Dynograph.
20 To assess the responsiveness of each dog,
isoproterenol was given i.v. at half-log interval doses
from 0.007 to 6.67 $\mu\text{g/kg}$. The test compound was then
administered intravenously at 1 mg/kg.

The test results are summarized in the following
25 table:

30

35

TABLE II

5	Compound	Dose (mg/kg)	<u>Peak Effects</u> <u>as % of Max. Isoproterenol</u>		
			Rt. Ventricular Contractile Force	Heart Rate	Blood Pressure
10	2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]-quinazolin-7-yl)-oxybutyramidyl)-acetic acid ^a	1 (i.v.) ^b	33	30	32

^a Suspended in carboxymethylcellulose.

^b i.v. = intravenous administration.

15

EXAMPLE 15

Antimetastatic activity against Lewis Lung Carcinoma
(Spontaneous Metastases)

Mice (female, C57B1/6, 16-18 g) were inoculated
 20 subcutaneously between the inguinal and axillary areas
 with 0.2 ml of a freshly prepared tumor brei. Control
 mice were treated with vehicle. Other mice were treated
 orally with test compound in suspension in 0.5%
 carboxymethylcellulose (CMC). Treatments were initiated
 25 one day after tumor implantation, and continued every
 other day throughout the experiment. 20 to 21 days after
 implantation of the tumor, mice were sacrificed, the
 primary tumor was weighed, and the number of lung
 metastases was determined by counting under a dissecting
 30 microscope. The results are shown in Table III.

35

TABLE III

5	Treatment	Number of Pulmonary Metastases	
		Median	Range
	Control	5	0-29
10	2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-7-yl)-oxybutyramidyl)acetic acid (5 mg/kg)	0*	0-11

*p<0.05

15

EXAMPLE 16

Six male Swiss-Webster mice (Bantin-Kingman) each weighing approximately 25 grams, were injected with a single subcutaneous dose of an aqueous solution of 2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-7-yl)oxybutyramide)acetic acid. The dosages were 250, 500, 1000 and 2000 mg/kg. The mice were observed twice daily for mortality for 21 days. No lethal effects were observed.


25

30

35

CLAIMS

1. A compound according to the formula



and the pharmaceutically acceptable salts thereof wherein:

m and n are integers of 1 to 6;

R₁ is hydrogen or alkyl of 1 to 4 carbon;

15 R₂ is hydrogen or R₁ and R₂ are combined to form a carbonyl group;

R₃ is hydrogen, alkyl of 1 to 6 carbons, phenyl, benzyl, hydroxy C₁₋₄ alkyl and its acylates, carbamoyl alkyl, carboxyalkyl, alkoxy carbonyl alkyl or amino acid side
20 chains;

R₄ is hydrogen, alkyl of 1 to 6 carbons, benzyl, or hydroxy C₁₋₄ alkyl;

R₅ is hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms or cycloalkyl lower alkyl of 4
25 to 12 carbon atoms wherein the cycloalkyl ring is unsubstituted or substituted with a C₁₋₄ alkyl, C₁₋₄ alkoxy, -OH, -OCOR₆, halo, -NH₂, -N(R₆)₂, -NHCOR₆, -COOH, or -COO(R₆) group wherein R₆ is C₁₋₄ alkyl; phenyl or phenyl C₁₋₄ alkyl wherein phenyl is unsubstituted or substituted with 1 or
30 more C₁₋₄ alkyl, halo or C₁₋₄ alkoxy groups or an -NH₂, -N(R₆)₂, -NHCOR₆, -COOH, or -COOR₆ group wherein R₆ is C₁₋₄ alkyl;

Y is hydrogen, alkyl or 1 to 4 carbon atoms, halo or C₁₋₄ alkoxy; and

35 Z is -OR₇ or -NR₇R₈ wherein R₇ and R₈ are independently

hydrogen or C₁₋₄ alkyl;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein Z is -OR₇
5 wherein R₇ is C₁₋₄ alkyl.

3. A compound of claim 2 wherein R₁, R₂ and R₃ are
hydrogen, R₄ is hydrogen or methyl, m is 1 - 3 and n is 3 or
4.

10

4. A compound according to claim 3 wherein R₄ is hydrogen,
m is 1, n is 3 or 4 and R₅ is alkyl of 1 to 6 carbon atoms,
cycloalkyl of 3 to 8 carbon atoms or cycloalkyl lower alkyl
of 4 to 12 carbon atoms.

15

5. A compound according to claim 4 wherein n is 3 and R₅
is alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 8
carbon atoms.

20 6. Methyl 2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydro-
imidazo[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetate or a
pharmaceutically acceptable salt thereof.

7. A compound according to claim 1 wherein Z is -OR₇
25 wherein R₇ is hydrogen.


8. A compound of claim 7 wherein R₁, R₂ and R₃ are
hydrogen, R₄ is hydrogen or methyl, m is 1 - 3 and n is 3 or
4.

30

9. A compound according to claim 8 wherein R₄ is hydrogen,
m is 1, n is 3 or 4 and R₅ is alkyl of 1 to 6 carbon atoms,
cycloalkyl of 3 to 8 carbon atoms or cycloalkyl lower alkyl
of 4 to 12 carbon atoms.

10. A compound according to claim 9 wherein n is 3 and R₅ is alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 8 carbon atoms.
- 5 11. 2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-7-yl)oxybutyramidyl)acetic acid or a pharmaceutically acceptable salt thereof.
12. A compound according to claim 1 wherein Z is -NH₂.
- 10 13. A compound of claim 12 wherein R₁, R₂ and R₃ are hydrogen, R₄ is hydrogen or methyl, m is 1 - 3 and n is 3 or 4.
- 15 14. A compound according to claim 13 wherein R₄ is hydrogen, m is 1, n is 3 or 4 and R₅ is alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms or cycloalkyl lower alkyl of 4 to 12 carbon atoms.
- 20 15. A compound according to claim 14 wherein n is 3 and R₅ is alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 8 carbon atoms.
16. 2-(N-cyclohexyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo-
25 [2,1-b]quinazolin-7-yl)oxybutyramidyl)acetamide or a pharmaceutically acceptable salt thereof.
17. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of any one of the
30 preceding claims.
18. A process for preparing compounds of claim 1, which process comprises either:
- (i) treating a compound of Formula II

5




wherein

10 m , n , R_1 , R_2 , R_3 , R_5 , Y and Z are as defined in claim 1
 but wherein R_5 , R_7 and R_8 are not hydrogen, with an N-
 alkylating agent, or

(ii) treating a compound of Formula III

15




20

wherein

25 m , n , R_1 , R_2 , R_3 , R_4 and Y are as defined in claim 1
 and Z is $-OR_7$ wherein R_7 is C_{1-4} alkyl, with base; or

(iii) treating a compound of Formula IV


30




35 wherein

m, n, R₁, R₂, R₃, R₅, and Y are defined in claim 1, Z is -OR₇ wherein R₇ is C₁₋₄ alkyl or -NR₇R₈ wherein R₇ and R₈ are hydrogen or C₁₋₄ alkyl and R₆ is alkyl of 1 to 6 carbon atoms;

- 5 , serially with a halocyanogen and base to form a compound of Formula I wherein R₄ is hydrogen; or
 (iv) treating a compound of Formula V



- 15 with 2-methylthiohydantoin and wherein m, n and Y are defined in claim 1 and Z is -OR₇ wherein R₇ is C₁₋₄ alkyl or -NR₇R₈ wherein R₇ and R₈ are defined in claim 1 to yield a compound of Formula I wherein R₁ and R₂ are a carbonyl group
 20 and R₃ and R₄ are both hydrogen; or
 (v) treating a compound of the formula



- 30 wherein n, R₁, R₂, R₃, R₄ and Y are as defined in claim 1 with an amide-forming reagent to form a compound of Formula I; or

 (vi) converting the free acid of a compound of Formula I to the corresponding amide; or

- 35 (vii) converting the free acid of a compound of Formula

- I to a pharmaceutically acceptable salt; or
 (viii) converting a salt to the compound of Formula I
to the corresponding free acid; or
 (ix) converting the free base of a compound of Formula
5 I to a pharmaceutically acceptable acid addition salt; or
 (x) converting a salt of the compound of Formula I to
the corresponding free base.
19. A compound according to any one of claims 1 to 16 for
10 use in the treatment of medical disorders.
20. The use of a compound of any one of claims 1 to 16 for
the manufacture of a medicament for inhibiting 3',5'-cyclic
AMP phosphodiesterase, or more generally an antithrombotic
15 medicament.
21. A compound of claim 19 wherein the use is for treating
heart failure.
- 20 22. A compound of claim 19 wherein the use is for
inhibiting tumor growth.

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 85300977.7

(22) Date of filing: 14.02.85

(51) Int. Cl.⁴: **C 07 D 487/04**

A 61 K 31/505

/(C07D487/04, 239:00, 235:00)

(30) Priority: 15.02.84 US 580409

(43) Date of publication of application:
28.08.85 Bulletin 85/35

(88) Date of deferred publication of search report: 15.07.87

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(71) Applicant: **SYNTEX (U.S.A.) INC.**
3401 Hillview Avenue
Palo Alto, California 94304(US)


(72) Inventor: **Fried, John H.**
1238 Martin Avenue
Palo Alto California 94301(US)

(72) Inventor: **Venuti, Michael C.**
44321 21st street
San Francisco California 94114(US)

(74) Representative: **Armitage, Ian Michael et al.**
MEWBURN ELLIS & CO. 2/3 Cursitor Street
London EC4A 1BQ(GB)

(54) **(2-Oxo-1,2,3,5-tetrahydroimidazo-/2,1-b/quinnazoliny)-oxyalkylamides, their preparation, compositions containing them and their use in making medicaments.**

(57) Compounds according to the formula



and their pharmaceutically acceptable salts.

These compounds are 3',5'-cyclic AMP phosphodiesterase inhibitors useful as antithrombotic agents and the like in mammals.



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
P, A	EP-A-0 116 948 (SYNTEX (U.S.A.) INC.) * claims 1, 26-30; page 3, line 26 - page 5, line 11 *	1,17-22	C 07 D 487/04 A 61 K 31/505// (C 07 D 487/04 C 07 D 239:00 C 07 D 235:00)
A	--- EP-A-0 000 718 (F. HOFFMANN-LA ROCHE & CO. AG) * claims 1, 7, 8, 14 *	1,17-21	
D, A	--- US-A-3 932 407 (W.N. BEVERUNG) * claim 1; abstract; columns 5, 6, chart I, step 2 *	1,17-21	
A	--- US-A-3 988 340 (R.A. PARTYKA et al.) * claim 1; abstract; examples 7, 8, 14 *	1,17-21	TECHNICAL FIELDS SEARCHED (Int. Cl. 4)
A	--- CHEMICAL ABSTRACTS, vol. 93, no. 3, 21st July 1980, page 691, column 1, abstract no. 26291r, Columbus, Ohio, US; & JP - A - 79 163 825 (OTSUKA PHARMACEUTICAL CO., LTD.) 26-12-1979 (Cat. D,A) -----	19,20	C 07 D 487/00
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 12-03-1987	Examiner HASS C V F
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			